Document:

Collaboration and License Agreement

 EXHIBIT 10.15 
  
 COLLABORATION AND LICENSE AGREEMENT 
  
 by and between 
  
 MERCK & CO., INC. 
  
 and 
  
 FOXHOLLOW TECHNOLOGIES, INC. 
  

					
			
	ARTICLE 1	  	DEFINITIONS	  	1
			
	 1.1
	  	 “Affiliate”
	  	1
			
	 1.2
	  	 “Background Package”
	  	2
			
	 1.3
	  	 “Biological Samples and Data”
	  	2
			
	 1.4
	  	 “Calendar Quarter”
	  	2
			
	 1.5
	  	 “Calendar Year”
	  	2
			
	 1.6
	  	 “Change of Control”
	  	2
			
	 1.7
	  	 “Collaboration Program”
	  	2
			
	 1.8
	  	 “Collaboration Program Clinical Study” or “CPCS”
	  	2
			
	 1.9
	  	 “Collaboration Program Inventions and Results”
	  	2
			
	 1.10
	  	 “Collaboration Program Patent Rights”
	  	3
			
	 1.11
	  	 “Collaboration Program Term”
	  	3
			
	 1.12
	  	 “Combination Product”
	  	3
			
	 1.13
	  	 “Committee” or “JCC”
	  	3
			
	 1.14
	  	 “Competing Pharma Change of Control”
	  	3
			
	 1.15
	  	 “Control”
	  	3
			
	 1.16
	  	 “CPCS Samples and Data”
	  	3
			
	 1.17
	  	 “CRO”
	  	3
			
	 1.18
	  	 “Data”
	  	4
			
	 1.19
	  	 “DDMAC”
	  	4
			
	 1.20
	  	 “Dose Ranging Product”
	  	4
			
	 1.21
	  	 “EMEA”
	  	4
			
	 1.22
	  	 “Enhanced Label Product”
	  	4
			
	 1.23
	  	 “Excluded Merck Compound Rights”
	  	4
			
	 1.24
	  	 “FDA”
	  	4
			
	 1.25
	  	 “FHT Collaboration Program Inventions and Results”
	  	4
			
	 1.26
	  	 “FHT Collaboration Program Patents”
	  	4
			
	 1.27
	  	 “FHT Independent Inventions and Improvements”
	  	4
			
	 1.28
	  	 “Filing”
	  	4
			
	 1.29
	  	 “First Commercial Sale”
	  	4
			
	 1.30
	  	 “Indication”
	  	5
			
	 1.31
	  	 “Information”
	  	5

  

 1. 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

					
			
	 1.32
	  	 “Initial Term”
	  	5
			
	 1.33
	  	 “Initiation”
	  	5
			
	 1.34
	  	 “Invention”
	  	5
			
	 1.35
	  	 “Joint Collaboration Program Inventions and Results”
	  	5
			
	 1.36
	  	 “Joint Patent Rights”
	  	5
			
	 1.37
	  	 “Labeled Product”
	  	5
			
	 1.38
	  	 “Major Indication”
	  	5
			
	 1.39
	  	 “Major Market”
	  	5
			
	 1.40
	  	 “Marketing Authorization”
	  	5
			
	 1.41
	  	 “Material” is defined in Section 1.3
	  	5
			
	 1.42
	  	 “Merck Collaboration Program Inventions and Results”
	  	5
			
	 1.43
	  	 “Merck Collaboration Program Patents”
	  	6
			
	 1.44
	  	 “Merck Independent Inventions and Improvements”
	  	6
			
	 1.45
	  	 “Merck NCE”
	  	6
			
	 1.46
	  	 “NDA”
	  	6
			
	 1.47
	  	 “Option Period”
	  	6
			
	 1.48
	  	 “Party”
	  	6
			
	 1.49
	  	 “Patent Rights”
	  	6
			
	 1.50
	  	 “Phase III Clinical Trial”
	  	6
			
	 1.51
	  	 “Product”
	  	6
			
	 1.52
	  	 “Product Exclusivity License”
	  	6
			
	 1.53
	  	 “Product Net Sales”
	  	6
			
	 1.54
	  	 “Profiled Compound”
	  	7
			
	 1.55
	  	 “Project Leader”
	  	7
			
	 1.56
	  	 “Promotional Material”
	  	7
			
	 1.57
	  	 “Prospective Registry”
	  	7
			
	 1.58
	  	 “Regulatory Authority”
	  	7
			
	 1.59
	  	 “Sample Criteria”
	  	8
			
	 1.60
	  	 “Tail Period”
	  	8
			
	 1.61
	  	 “TALON Registry”
	  	8
			
	 1.62
	  	 “Territory”
	  	8
			
	 1.63
	  	 “Test”
	  	8

  

 2. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

					
			
	 1.64
	  	 “Test Exclusivity License”
	  	8
			
	 1.65
	  	 “Test Field”
	  	8
			
	 1.66
	  	 “Test Net Sales”
	  	8
			
	 1.67
	  	 “Therapeutic Product”
	  	8
			
	 1.68
	  	 “Third Party”
	  	9
			
	 1.69
	  	 “Trigger”
	  	9
			
	 1.70
	  	 “Work Plan”
	  	9
			
	 1.71
	  	 “Valid Product Patent Claim”
	  	9
			
	 1.72
	  	 “Valid Test Patent Claim”
	  	9
			
	ARTICLE 2	  	 COLLABORATION PROGRAM
	  	9
			
	 2.1
	  	 Work Plan
	  	9
			
	 2.2
	  	 Collaboration Program Oversight and Management
	  	9
			
	 2.3
	  	 General Collaboration Program Responsibilities
	  	11
			
	 2.4
	  	 Specific Collaboration Program Responsibilities
	  	12
			
	 2.5
	  	 FHT Representations Regarding Use of Biological Samples and Data
	  	17
			
	 2.6
	  	 Records and Reports
	  	17
			
	 2.7
	  	 Rights to Collaboration Program Inventions and Results
	  	17
			
	 2.8
	  	 Collaboration Program Term
	  	18
			
	 2.9
	  	 Exclusive Efforts
	  	18
			
	 2.10
	  	 No Encumbrances
	  	19
			
	ARTICLE 3	  	 LICENSES; EXCHANGE OF INFORMATION; DEVELOPMENT AND COMMERCIALIZATION
	  	19
			
	 3.1
	  	 FHT License Grants to Merck
	  	19
			
	 3.2
	  	 Merck License Grants to FHT
	  	21
			
	 3.3
	  	 No Implied Licenses
	  	22
			
	ARTICLE 4	  	 CONFIDENTIALITY AND PUBLICATION
	  	22
			
	 4.1
	  	 Nondisclosure Obligation
	  	22
			
	 4.2
	  	 Publication
	  	23
			
	 4.3
	  	 Publicity/Use of Names
	  	24
			
	ARTICLE 5	  	 COLLABORATION PROGRAM FUNDING, MILESTONES AND ROYALTIES
	  	24
			
	 5.1
	  	 Initial Collaboration Program Fees
	  	25
			
	 5.2
	  	 Registry Access and Prospective Registry Fees
	  	25

  

 3. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

					
			
	 5.3
	  	 Initial Clinical Study Funding Fee
	  	24
			
	 5.4
	  	 Additional Payments
	  	24
			
	 5.5
	  	 Therapeutic Product Development Milestones Under the Non-Exclusive License
	  	25
			
	 5.6
	  	 Test Development Milestones Under the Non-Exclusive License
	  	26
			
	 5.7
	  	 Payments if Merck Triggers the Product Exclusivity License
	  	26
			
	 5.8
	  	 Therapeutic Product Development Milestones Under the Exclusive License
	  	26
			
	 5.9
	  	 Payments if Merck Triggers the Test Exclusivity License
	  	27
			
	 5.10
	  	 Therapeutic Product and Test Development Milestones – General
	  	27
			
	 5.11
	  	 Royalties on Test and Product Sales
	  	28
			
	 5.12
	  	 Royalties – General
	  	28
			
	 5.13
	  	 Reports; Payment of Royalty
	  	29
			
	 5.14
	  	 Audits
	  	29
			
	 5.15
	  	 Payment Exchange Rate
	  	30
			
	 5.16
	  	 Income Tax Withholding
	  	30
			
	 5.17
	  	 Sharing Certain Sublicense Revenue
	  	30
			
	ARTICLE 6	  	 REPRESENTATIONS AND WARRANTIES
	  	31
			
	 6.1
	  	 Representations and Warranties of Each Party
	  	31
			
	 6.2
	  	 FHT Representations and Warranties
	  	31
			
	ARTICLE 7	  	 PATENT PROVISIONS
	  	32
			
	 7.1
	  	 Independent Inventions and Improvements
	  	32
			
	 7.2
	  	 Filing, Prosecution and Maintenance of Collaboration Patents
	  	32
			
	 7.3
	  	 Joint Collaboration Program Patents
	  	33
			
	 7.4
	  	 Interference, Opposition, Reexamination and Reissue
	  	34
			
	 7.5
	  	 Enforcement and Defense
	  	34
			
	 7.6
	  	 Patent Term Restoration
	  	36
			
	ARTICLE 8	  	 TERM AND TERMINATION
	  	36
			
	 8.1
	  	 Term and Expiration
	  	36
			
	 8.2
	  	 Termination by Merck of the Collaboration Program
	  	36
			
	 8.3
	  	 Termination for Cause
	  	36
			
	 8.4
	  	 Effect of Expiration or Termination; Survival
	  	39

  

 4. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

					
			
	ARTICLE 9	  	 MISCELLANEOUS
	  	40
			
	 9.1
	  	 Indemnification
	  	40
			
	 9.2
	  	 Force Majeure
	  	41
			
	 9.3
	  	 Assignment and Change of Control
	  	41
			
	 9.4
	  	 Severability
	  	42
			
	 9.5
	  	 Notices
	  	42
			
	 9.6
	  	 Applicable Law
	  	43
			
	 9.7
	  	 Dispute Resolution
	  	43
			
	 9.8
	  	 Entire Agreement; Amendments
	  	44
			
	 9.9
	  	 Headings
	  	45
			
	 9.10
	  	 Independent Contractors
	  	45
			
	 9.11
	  	 Waiver
	  	45
			
	 9.12
	  	 Cumulative Remedies
	  	45
			
	 9.13
	  	 Waiver of Rule of Construction
	  	45
			
	 9.14
	  	 Certain Conventions
	  	45
			
	 9.15
	  	 Business Day Requirements
	  	45
			
	 9.16
	  	 Counterparts
	  	45

  

 5. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 COLLABORATION AND LICENSE AGREEMENT 
  
 This Collaboration and License Agreement (this “Agreement”) is effective as of September 14, 2005, (the “Effective
Date”) and is entered into by and between Merck & Co., Inc., a New Jersey corporation, having offices at One Merck Drive, Whitehouse Station, New Jersey (“Merck”), and FoxHollow Technologies, Inc., a Delaware corporation,
having offices at 740 Bay Road, Redwood City, California (“FHT”). 
  
 Background: 
  

	A.	FHT develops and markets minimally invasive plaque excision devices for the treatment of peripheral artery diseases, and owns and maintains the TALON Registry (as further defined
below). Merck discovers, develops and markets vaccines and medicines. 

  

	B.	FHT and Merck each believe that the other brings significant and complementary strengths to a potentially effective collaboration involving the establishment of methodologies to
conduct clinical trials to study atherosclerotic plaque, and the use of excised plaque and related data to identify proteins that may be predictive of cardiovascular events. 

  

	C.	Merck and FHT wish to enter into a collaboration on the terms and subject to conditions set out in this Agreement. In addition, Merck desires an option to obtain exclusive licenses
under certain intellectual property rights arising from the collaboration, and FHT desires to grant such an option, on the terms and subject to conditions set out in this Agreement. 

  
 NOW, THEREFORE, Merck and FHT agree as follows:

  
 ARTICLE 1 DEFINITIONS. Unless specifically set forth to the contrary
in this Agreement, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below.  
  

	1.1	“Affiliate” means (a) any corporation or business entity of which fifty percent (50%) or more of the securities or other ownership interests representing
the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by Merck or FHT; or (b) any corporation or business entity which, directly or indirectly, owns, controls or holds fifty percent
(50%) (or the maximum ownership interest permitted by law) or more of the securities or other ownership interests representing the equity, the voting stock or, if applicable, the general partnership interest, of Merck or FHT; or (c) any
corporation or business entity of which fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly,
by a corporation or business entity described in (a) or (b). 

  

 1 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	1.2	“Background Package” means the background package submitted to the FDA for the end-of-Phase II meeting between Merck (or its Affiliate) and the FDA to prepare for
implementation of a Phase III Clinical Trial. 

  

	1.3	“Biological Samples and Data” means: 

  

	 	(a)	biological material (“Material”) directly obtained from human or animals, or derivatives of such materials, and collected or tested under the Collaboration Program.

  
 Examples of Material include [ * ] and [ * ]
contained in the [ * ] , and all [ * ] that meets [ * ] , and all [ * ] , as well as any [ * ] from [ * ] or [ * ] ; and 
  

	 	(b)	information generated from the testing or use of Material, or information concerning the source of such Material (“Data”). 

  
 Examples of such Data include [ * ] concerning or resulting from the [ * ]
of any Material. This includes [ * ] found in [ * ] at different [ * ] , and all [ * ] , as well as any [ * ] . 
  

	1.4	“Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and
December 31. 

  

	1.5	“Calendar Year” means each successive period of twelve (12) months starting on January 1 and ending on December 31. 

  

	1.6	“Change of Control” shall mean with respect to a Party: (a) the sale of all or substantially all of such Party’s assets or business relating to this
Agreement; (b) a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power
of the surviving entity immediately after such merger, reorganization or consolidation; or (c) the acquisition by a person or entity, or group of persons or entities acting in concert, of more than fifty percent (50%) of the voting equity
securities or management control of such Party. 

  

	1.7	“Collaboration Program” means the activities undertaken by the Parties under this Agreement during the Collaboration Program Term. Initial activities are as set out
in Article 2 and the Work Plan. 

  

	1.8	“Collaboration Program Clinical Study” or “CPCS” means a clinical study conducted under the Collaboration Program in accordance with a protocol that has
been approved by the JCC. 

  

	1.9	“Collaboration Program Inventions and Results” means: 

  

	 	(a)	all Biological Samples and Data; 

  

	 	(b)	 all Inventions, protocols, results, data, discoveries, formulas, know-how 

  

 2 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	 	 
and trade secrets, including any biomarkers or surrogate markers, assays, tests, clinical trial methodologies, or procedures (in each case whether patentable
or otherwise) that were generated in the course of or arise from the performance of the Collaboration Program, or resulting from the analysis of Biological Samples and Data during the Collaboration Program Term or Tail Period; and

  

	 	(c)	any improvements or enhancements to, or subsequent inventions resulting from, any of the items described in clauses (a) and (b) to the extent such improvements,
enhancements or inventions are generated during the Collaboration Program Term or Tail Period; provided, however the term “Collaboration Program Inventions and Results” shall not apply to, and shall exclude, FHT Independent
Inventions and Improvements, Excluded Merck Compound Rights, and Merck Independent Inventions and Improvements. 

  

	1.10	“Collaboration Program Patent Rights” means any and all patents and patent applications (which for the purposes of this Agreement shall be deemed to include
certificates of invention, provisional applications, and applications for certificates of invention) claiming any Collaboration Program Invention and Results. 

  

	1.11	“Collaboration Program Term” means the duration of the Collaboration Program, as described more fully in Section 2.8. 

  

	1.12	“Combination Product” means a product containing both a Therapeutic Product as well as one or more active ingredients that are other than a Profiled Compound. All
references to Product in this Agreement shall be deemed to include Combination Products. 

  

	1.13	“Committee” or “JCC” means the committee established to facilitate and direct the Collaboration Program, as more fully described in Section 2.2.2.

  

	1.14	“Competing Pharma Change of Control” means a Change of Control in which the acquirer is a company or group of companies acting in concert (a) for whom
collective worldwide sales of pharmaceutical products in the Calendar Year that preceded the year in which the Change of Control was consummated were [ * ] United States dollars [ * ] or more, or (b) who have an active clinical development or
commercialization program for any pharmaceutical or diagnostic product intended to treat, prevent and/or diagnose a Major Indication. 

  

	1.15	“Control” with respect to intellectual property or tangible property rights (e.g., compounds or information), means the legal authority (whether by ownership or
license, other than pursuant to this Agreement) of a Party to grant access to, or a license or sublicense of such intellectual property rights or tangible property. 

  

	1.16	“CPCS Samples and Data” is defined in Section 2.4.9(c). 

  

	1.17	“CRO” means a contract research organization. 

  

 3 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	1.18	“Data” is defined in Section 1.3. 

  

	1.19	“DDMAC” means the FDA’s Division of Drug Marketing, Advertising, and Communications. 

  

	1.20	“Dose Ranging Product” means a Therapeutic Product that achieved those Product Non-Exclusivity development milestones [ * ] described in Section 5.5(a)(i) and
5.5(c), or those Product Exclusivity development milestones [ * ] described in Section 5.8(a)(i) and 5.8(c). 

  

	1.21	“EMEA” means the European Medicines Agency. 

  

	1.22	“Enhanced Label Product” means a Therapeutic Product with respect to which any Collaboration Inventions and Results are contained in both: (i) [ * ] and
(ii) [ * ] used by Merck or its Affiliates in the United States for such Therapeutic Product. 

  

	1.23	“Excluded Merck Compound Rights” means all Merck NCEs (and any uses, formulations or enhancements to the same), and all data on Merck NCEs.

  

	1.24	“FDA” means the United States Food and Drug Administration. 

  

	1.25	“FHT Collaboration Program Inventions and Results” means all Collaboration Program Inventions and Results discovered, developed or invented solely by employees of
FHT, or other persons not employed by Merck acting on behalf of FHT. 

  

	1.26	“FHT Collaboration Program Patents” means all Collaboration Program Patent Rights that claim FHT Collaboration Program Inventions and Results.

  

	1.27	“FHT Independent Inventions and Improvements” means: (a) FHT-Controlled technology, methods, devices, and systems for the excision of plaque; (b) the
TALON Registry (excluding any Material contained therein that meets the Sample Criteria); (c) any improvements to the items listed in (a) created under the Collaboration Program or independent of the Collaboration Program but after the
Effective Date; and (d) FHT patents, patent applications and know-how covering any of the foregoing. 

  

	1.28	“Filing” means the acceptance by the first Regulatory Authority of an NDA for filing. 

  

	1.29	“First Commercial Sale” means, with respect to any Product or Test, the first sale for end use or consumption of such Product or Test in a country, excluding,
however, any sale or other distribution for use in clinical trials. 

  

 4 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	1.30	“Indication” means a separate and distinct disease or medical condition in humans (a) which a Therapeutic Product is intended to treat, and/or prevent, where
the Therapeutic Product is either in Phase III Clinical Trials, or is the subject of an NDA; and/or (b) for which a Therapeutic Product has received Marketing Authorization (meaning that such Indication is contained in the Therapeutic
Product’s labeling approved by a Regulatory Authority as part of the Marketing Authorization for such Product). 

  

	1.31	“Information” means all information and data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party
under this Agreement. 

  

	1.32	“Initial Term” is defined in Section 2.8. 

  

	1.33	“Initiation” means, with respect to a Phase III Clinical Trial, the administration of the first dose to the first patient in such Phase III Clinical Trial.

  

	1.34	“Invention” means any process, method, composition of matter, article of manufacture, discovery or finding that is conceived and/or reduced to practice in the
course of the activities of the Collaboration Program. 

  

	1.35	“Joint Collaboration Program Inventions and Results” means all Collaboration Program Inventions and Results discovered, developed or invented jointly by employees
of Merck and FHT, or others acting on behalf of Merck and FHT. 

  

	1.36	“Joint Patent Rights” means all Collaboration Program Patent Rights that claim Joint Collaboration Program Inventions and Results. 

  

	1.37	“Labeled Product” means any Therapeutic Product with respect to which any Collaboration Inventions and Results are contained in the [ * ] , but are not contained in
[ * ] used by Merck or its Affiliates in the United States for such Therapeutic Product. 

  

	1.38	“Major Indication” means any of the following Indications[ * ] . 

  

	1.39	“Major Market” means any the following: United States of America, Japan, and either (i) the European Union, in the case of EMEA centralized procedure for drug
approval, or (ii) France, Germany, Italy, the United Kingdom, or Spain, in the case where Merck or its Affiliates does not make use of the EMEA centralized procedure for drug approval. 

  

	1.40	“Marketing Authorization” means all approvals necessary from the relevant Regulatory Authority to market and sell a Therapeutic Product or Test (including without
limitation all applicable pricing and governmental reimbursement approvals even if not legally required to sell Product or Test in a country). 

  

	1.41	“Material” is defined in Section 1.3. 

  

	1.42	“Merck Collaboration Program Inventions and Results” means all Collaboration Program Inventions and Results discovered, developed or invented solely by employees of
Merck, or other persons not employed by FHT acting on behalf of Merck. 

  

 5 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	1.43	“Merck Collaboration Program Patents” means all Collaboration Program Patent Rights that claim Merck Collaboration Program Inventions and Results.

  

	1.44	“Merck Independent Inventions and Improvements” means (a) Merck-Controlled compounds (including Merck NCEs), methods of treatment, analysis technology,
clinical specimens (other than Biological Samples and Data), biomarkers, and assays; (b) any improvements on the same created under the Collaboration Program or independent of the Collaboration Program but after the Effective Date; and
(c) Merck (including Affiliate) patents, patent applications, and know how covering any of the foregoing. 

  

	1.45	“Merck NCE” means any Merck-Controlled Profiled Compound that has not received FDA approval for sale as a human use product at the time it is studied in the
Collaboration Program. 

  

	1.46	“NDA” means a New Drug Application, Biologics License Application, or Marketing Application Authorization, or similar application or submission for Marketing
Authorization filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or diagnostic product in country or in group of countries within the jurisdiction of the Regulatory Authority. 

  

	1.47	“Option Period” means the period starting on the Effective Date and ending [ * ] days after the expiration or termination of the Collaboration Program Term, and at
any time therein. 

  

	1.48	“Party” means Merck or FHT, and “Parties” shall mean Merck and FHT. 

  

	1.49	“Patent Rights” means both the FHT Collaboration Program Patent Rights and FHT’s interest in the Joint Collaboration Program Patent Rights.

  

	1.50	“Phase III Clinical Trial” means a human clinical trial that is pivotal to Filing and satisfies the requirements of 21 CFR 312.21(c). 

 

	1.51	“Product” means each of the Dose Ranging Product, Labeled Product and Enhanced Labeled Product, and each “Products” means all such products, collectively.
“Product” also includes any Combination Product. 

  

	1.52	“Product Exclusivity License” is defined in Section 3.1.3(b)(ii). 

  

	1.53	“Product Net Sales” means the gross invoice price of Product sold by Merck, its Affiliates and their respective sublicensees to the first Third Party after
deducting, if not previously deducted, from the amount invoiced or received: 

  

	 	1.53.1	trade and quantity discounts other than early pay cash discounts; 

  

	 	1.53.2	returns, rebates, chargebacks and other allowances; 

  

	 	1.53.3	the standard inventory cost of devices or delivery systems used for dispensing or administering Product (such as syringes or inhalation devices, but not packaging);

  

 6 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	 	1.53.4	sales commissions paid to Third Party distributors and/or selling agents, in amounts customary to the trade and to the extent allocable to the Product; 

  

	 	1.53.5	retroactive price reductions that are actually allowed or granted; and 

  

	 	1.53.6	a fixed amount equal to [ * ] to cover bad debt, sales or excise taxes, early payment cash discounts, transportation and insurance, custom duties, and other governmental charges.

  
 With respect to sales of Combination Products,
Net Sales shall be calculated on the basis of the gross invoice price of Product(s) containing the same strength of Profiled Compound sold, without other active ingredients. If the Therapeutic Product contained within any Product is not sold
separately, Net Sales shall be calculated on the basis of the gross invoice price of the Combination Product multiplied by a fraction, the numerator of which shall be the [ * ] and the denominator of which shall be the [ * ] in the Combination
Product. Inventory cost shall be determined in accordance with Merck’s regular accounting methods, consistently applied. The deductions set out in Sections 1.53.1 through 1.53.6 will be applied in calculating Net Sales for a Combination
Product. If Product is sold only as a Combination Product and either Party reasonably believes that the calculation set forth in this paragraph does not fairly reflect the value of the Product relative to the other active ingredients in the
Combination Product, the Parties shall negotiate, in good faith, other means of calculating Net Sales with respect to Combination Products 
  

	1.54	“Profiled Compound” means any chemical compound (including but not limited to small molecules, proteins, antibodies and therapeutic nucleic acids): (a) for
which Biological Samples and Data is generated concerning such compound’s effectiveness; or (b) the discovery, identification or development of which utilizes or is based upon Collaboration Program Inventions and Results.

  

	1.55	“Project Leader” is defined in Section 2.2.1. 

  

	1.56	“Promotional Material” means any material for promotion of a Therapeutic Product in the United States that Merck prepares and that it is required to submit to DDMAC
on FDA transmittal Form 2253 (pursuant to 21 CFR 314.81) for a Therapeutic Product, including brochures, booklets, detailing pieces, advertisements published in journals, magazines, other periodicals and newspapers, or broadcast through media such
as radio, television, and telephone communications systems, to the extent Merck (or its Affiliate) has approved and obtains FDA approval for same for use in the United States. 

  

	1.57	“Prospective Registry” means the tissue and data collection registry created under the Collaboration Program, as more fully described in Section 2.4.2.

  

	1.58	“Regulatory Authority” means the FDA, EMEA, and, with respect to Japan, the Japanese governmental regulatory authority involved in granting approvals for the
manufacturing, marketing, reimbursement and/or pricing of a Product or Test in the Japan, and any successor governmental authority having substantially the same function. 

  

 7 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	1.59	“Sample Criteria” is defined in Section 2.4.4. 

  

	1.60	“Tail Period” means the [ * ] month period immediately following the end of the Collaboration Program Term. 

  

	1.61	“TALON Registry” means: (a) FHT’s multi-center registry designed to capture and archive patient outcomes data, as well as all biological material, such as
excised plaque using FHT technology, which such registry is expected to be closed prior to or shortly after the Effective Date, and (b) any and all de-identified patient-related clinical and demographic data corresponding to such biological
material, as well as any genetic, and genomic data associated with such collections. TALON Registry is further described in Exhibit 1.61. 

  

	1.62	“Territory” means all of the countries in the world, and their territories and possessions. 

  

	1.63	“Test” means (a) a prognostic test [ * ] and/or (b) a diagnostic test [ * ] ; and/or (ii) [ * ] ; to the extent the test described in (a) or
(b) was developed, discovered or identified by Merck using Collaboration Program Inventions and Results. 

  

	1.64	“Test Exclusivity License” is defined in Section 3.1.3(b)(i). 

  

	1.65	“Test Field” means the development, use and commercialization of Tests. 

  

	1.66	“Test Net Sales” mean the gross invoice price of Tests sold by Merck, its Affiliates and their respective sublicensees to the first Third Party after deducting, if
not previously deducted, from the amount invoiced or received: 

  

	 	1.66.1	trade and quantity discounts other than early pay cash discounts; 

  

	 	1.66.2	allowances actually credited to such Third Party for spoiled, damaged, outdated or returned Tests; and 

  

	 	1.66.3	a fixed amount equal to [ * ] of the amount invoiced to cover bad debt, sales or excise taxes, early payment cash discounts, transportation and insurance, custom duties, and other
governmental charges. 

  
 If Merck sells a Test in
the form of kit containing items developed, discovered or identified by Merck using Collaboration Inventions and Results, together with other diagnostic or prognostic items that were developed, discovered or identified without the use of
Collaboration Invention and Results, the Parties shall negotiate, in good faith, other means of calculating Net Sales with respect to such Test kits to fairly reflect the value of the Collaboration Inventions and Results relative to the other items
in the Test kit. 
  

	1.67	“Therapeutic Product” means any pharmaceutical or biological preparation in final form containing a Profiled Compound for: (a) sale by prescription,
over-the-counter or any other method; or (b) administration to human patients in a Phase III Clinical Trial. 

  

 8 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	1.68	“Third Party” shall mean an entity other than Merck and its Affiliates, and FHT and its Affiliates. 

  

	1.69	“Trigger” shall mean the exercise by Merck of its right to obtain either the Product Exclusivity License or Test Exclusivity License, as the case may be, as set
forth in Section 3.1.3(b), upon the payment set forth 5.9 and 5.7.1, respectively prior to the end of the Option Period. 

  

	1.70	“Work Plan” is described in Section 2.1. 

  

	1.71	“Valid Product Patent Claim” means a claim of an issued and unexpired Merck-Controlled patent claiming the composition of matter of a Product which claim has not
been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which decision is not appealable or has not been appealed within the time allowed for appeal, and which claim has not
been disclaimed, denied or admitted by Merck to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise. 

  

	1.72	“Valid Test Patent Claim” means a claim of an issued and unexpired claim within the Collaboration Program Patents Right which claim has not been revoked or held
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which decision is not appealable or has not been appealed within the time allowed for appeal, and which claim has not been disclaimed,
denied or admitted by Merck to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise. 

  
 ARTICLE 2 COLLABORATION PROGRAM 
  

	2.1	Work Plan. FHT and Merck shall engage in and conduct the Collaboration Program on the terms and subject to the conditions set out in this Agreement. The initial Work Plan
attached as Schedule 2.1 is an outline description of specific activities to be undertaken by each of the Parties during the Initial Term. The Project Leaders shall use their good faith efforts to agree upon further details of such activities
and develop a complete initial Work Plan for JCC approval no later than fifteen (15) days after the Effective Date. Subject to review and adjustment by the JCC, the Work Plan will set forth expectations with respect to each Party’s
relative contributions to the Collaboration Program. The JCC will periodically review, consider and approve revisions to the Work Plan as it deems appropriate. In addition, the Work Plan will be amended to describe with specificity the Collaboration
Program Clinical Studies to be undertaken under the Collaboration Program, and the projected timeframe for such studies. 

  

	2.2	Collaboration Program Oversight and Management. 

  

	 	2.2.1	 Project Leaders. The project leaders (“Project Leaders”) for the Collaboration Program are [ * ] for FHT, and [ * ] for Merck. The Project Leaders
shall have responsibility for developing and updating the Work Plan (for approval by the JCC), providing day-to-day direction and oversight of the Collaboration Program, 

  

 9 
 [
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	 	 
and presenting the JCC with periodic progress reports (but no less than once per quarter) describing the work performed and the results achieved to date on
the Collaboration Program. Each Party is entitled to designate a replacement Project Leader reasonably acceptable to the other Party, but shall notify the other Party in writing as soon as practicable upon the changing of its Project Leader.

  

	 	2.2.2	Committee. The Parties will establish a joint collaboration committee (the “Committee” or “JCC”) with equal representation from FHT and Merck of no less
than two and no more than four representatives each (who may be substituted or replaced by alternates at any time), to direct and oversee the Collaboration Program during the Collaboration Program Term. The JCC will be formed as soon as practicable
after the Effective Date to: 

  

	 	(a)	coordinate, implement, review, evaluate and prioritize Collaboration Program activities; 

  

	 	(b)	receive and review reports, results and data concerning research being conducted under the Collaboration Program, and exchange information and materials relating thereto;

  

	 	(c)	review, consider and approve revisions to the Work Plan and Collaboration Program Clinical Study protocols; 

  

	 	(d)	establish procedures relating to the harvesting, transfer and handling of Biological Samples and Data, and 

  

	 	(e)	determine the protocol to be used in the Prospective Registry, the quality control criteria for CPCS Samples and Data described in Section 2.4.9(c), and the Sample Criteria
described in Section 2.4.3. 

  

	 	2.2.3	JCC Chair. Merck shall appoint a representative to act as the JCC Chair. The JCC Chair shall have authority to call JCC meetings, and be responsible for circulating agenda
and performing administrative tasks required to assure efficient operation of the JCC, but shall have no additional voting rights. 

  

	 	2.2.4	JCC Meetings. The Committee shall meet in accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than once per Calendar
Quarter, with the location for such meetings alternating between FHT and Merck facilities (or such other location may be determined by the Committee). Alternatively, the Committee may meet by means of teleconference, videoconference or other similar
communications equipment. 

  

	 	2.2.5	 JCC Decision Making. The JCC will act by unanimous vote, with each of Merck and FHT having one vote. The members of the JCC will attempt in good faith to
reach consensus on all matters brought before the JCC, provided that if consensus on an issue cannot be reached, the issue in dispute will be promptly referred to the Senior Vice President of Merck Research Laboratories responsible 

  

 10 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
for worldwide licensing and external scientific affairs and the Chief Executive Officer of FHT for resolution, and if they cannot agree:

  

	 	(a)	FHT will have the final decision-making authority with respect to issues involving the methods or procedures for harvesting and collecting of tissue, and 

 

	 	(b)	Merck will have the final decision-making authority with respect to all other matters subject to decision by the JCC; provided, however, that Merck shall not have the final
decision-making authority with respect to decisions which require that FHT expend additional amounts other than those for which it is paid by Merck hereunder pursuant to Section 5.3 and 5.4, including any budgets to be approved by the JCC
pursuant to Section 2.4.9(d). 

  

	 	2.2.6	Restrictions on JCC. Notwithstanding anything the contrary in this Agreement, the JCC shall have no power to amend this Agreement (with the exception of the Work Plan as
provided in Section 2.1), or to resolve disputes between the Parties with respect to the interpretation of this Agreement, either Party’s performance of its obligations hereunder, or the ownership of intellectual property.

  

	2.3	General Collaboration Program Responsibilities. 

  

	 	2.3.1	FHT and Merck each shall conduct the Collaboration Program obligations in good scientific manner, and in compliance in all material respects with all requirements of applicable
laws, rules and regulations and attempt to achieve their respective objectives efficiently and expeditiously. FHT and Merck shall each proceed diligently with the work set out in the Work Plan by using their respective good faith efforts to allocate
sufficient time, effort, equipment and facilities to the Collaboration Program. Merck and FHT shall each use personnel with sufficient skills and experience as are required to accomplish the Collaboration Program in accordance with the terms of this
Agreement and the Work Plan. Each Party shall bear the cost of performing all approved Work Plan responsibilities assigned to it. 

  

 11 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	2.3.2	Merck is entitled to utilize the services of its Affiliates and Third Parties to perform its Collaboration Program activities; provided that Merck shall notify in writing FHT
periodically as to the identify of any such Merck Affiliates and Third Parties to the extent not disclosed to the JCC. FHT shall be entitled to utilize the service of Third Parties to perform its Collaboration Program activities only upon
Merck’s prior written consent, or as specifically set forth in Work Plan. Each Party is entitled to use the services of Third Parties that have been pre-approved by the JCC to carry out routine Collaboration Program activities, without the need
for obtaining the other Party’s prior written consent. Notwithstanding any such consent or pre-approval, both Parties shall remain at all times fully liable for its respective responsibilities under the Collaboration Program. Each Party
certifies that it has not, and will not, employ or otherwise use in any capacity the services of any person debarred under United States law, including but not limited to Section 21 USC 335a, in performing any portion of its Collaboration
Program responsibilities. 

  

	2.4	Specific Collaboration Program Responsibilities. Unless otherwise specified in the Work Plan, the Parties will have the following specific Collaboration Program
responsibilities. 

  

	 	2.4.1	TALON Registry Biological Samples and Data. FHT owns and shall be responsible for maintaining the TALON Registry, and shall be responsible for providing access to Merck to
the Biological Samples and Data resulting from the TALON Registry. 

  

	 	2.4.2	Prospective Registry Components. FHT shall be responsible for collecting the components of the Prospective Registry. The Parties anticipate that the Prospective Registry will
be made up of Biological Samples and Data collected from the following sources: 

  

	 	(a)	CPCS subjects who were not provided with any drug compounds, including any Merck NCEs; 

  

	 	(b)	TALON Registry Materials and Data that meet the Sample Criteria; and 

  

	 	(c)	Peripheral arterial disease and coronary disease plaque excision procedures conducted by or on behalf of FHT after the Effective Date that do not involve the study of Profiled
Compounds. This category will be made up of Biological Samples and Data collected by physicians using FHT’s excision devices. 

  

	 	2.4.3	 Ownership and Delivery of Prospective Registry Material and CPCS Samples and Data. Notwithstanding anything to the contrary in Section 2.7, Merck shall
own the Material contained in the Prospective Registry and the CPCS Samples and Data, provided, however, if Merck does not Trigger the Product Exclusivity License, Merck shall provide FHT with reasonable access to Material contained in the
Prospective Registry or the CPCS Samples and Data (other than 

  

 12 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
Material pertaining to Excluded Merck Compound Rights) to the extent such Material may be readily available and capable of being shared with FHT. From time
to time during the Collaboration Program Term as reasonably requested by Merck and in accordance with Merck’s reasonable instructions (or as may be set forth in the Work Plan), FHT shall transfer to Merck the Prospective Registry Material and
the CPCS Samples and Data, along with a complete set of Data associated with such Material. 

  

	 	2.4.4	Collection of Biological Samples and Data Meeting Sample Criteria. As part of the Prospective Registry protocol described in Section 2.2.2(e), the JCC shall
establish criteria (“Sample Criteria”) that Biological Samples and Data comprising the Prospective Registry are intended to meet. FHT shall use commercially reasonable efforts to collect and deliver to Merck: 

  

	 	(a)	[ * ] Biological Samples and Data that satisfy the Sample Criteria, but in no event shall FHT be required to collect and deliver to Merck more than 

  

	 	(b)	[ * ] Biological Samples and Data collected under the JCC-approved protocol. 

  

For clarity, each distinct “Biological Sample and Data” described in this Section would include [ * ] a given patient [ * ] on a given day.
A single Biological Sample and Data could thus be [ * ] from a [ * ] , as long as [ * ] on the [ * ] . Merck understands and acknowledges that FHT’s ability to collect such number of Biological Samples and Data referred to above is dependent
upon the JCC’s approval of the required protocol and Sample Criteria promptly following the Effective Date. 
  
 At least [ * ] of the Biological Samples and Data described in subsections 2.4.4(a) and (b) are required to be collected from [ * ] , as opposed to
[ * ] . 
  
 In addition, as instructed by the JCC, the Parties
will collaborate in the analysis of Biological Samples and Data within the TALON Registry to determine whether and to what extent they may meet the Sample Criteria. Any TALON Registry Biological Samples and Data meeting the Sample Criteria shall be
included in the Prospective Registry, and shall be counted when determining whether FHT has delivered the requisite numbers of Biological Samples and Data referred to in 2.4.4(a) and (b) above. 
  
 Once the JCC determines that either [ * ] Biological Samples and Data
described in 2.4.4(a), or [ * ] Biological Samples and Data described in 2.4.4(b) have been collected and delivered to Merck, the JCC will notify Merck and FHT accordingly. 
  

 13 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	2.4.5	Compounds and Biological Sample Analysis. Merck shall be responsible for, and shall bear the cost of, providing compounds to be profiled in the Collaboration Program or used
in any CPCSs. Merck, itself or through its Affiliates, shall also be responsible for analyzing Biological Samples and Data in an effort to establish plaque biomarkers of atherosclerotic disease activity. 

  

	 	2.4.6	Profiling. During the course of the Collaboration Program Term (provided that the Collaboration Program Term has been extended beyond the Initial Term), Merck will use
reasonable commercial efforts to study [ * ] Merck NCEs in either one or more CPCSs or as otherwise utilizing the clinical trial methodology described in Section 2.4.8. If Merck exercises its Product Exclusivity License but fails to have so
studied [ * ] Merck NCEs by the [ * ] of the end of the Collaboration Program Term, then FHT’s obligations under Section 2.9 shall expire thirty (30) days after such [ * ] unless, during such thirty (30) day period, Merck pays
FHT [ * ] payment for each of such [ * ] Merck NCEs not so studied by the end of such time period. 

  

	 	2.4.7	Regulatory Matters. 

  

	 	(a)	During the Collaboration Program Term and thereafter, Merck shall be solely responsible for, and shall bear the cost of, preparing and submitting registration dossiers for
Therapeutic Products, Products and Tests in the Territory; provided, that Merck shall provide FHT with the regulatory reports as described in Section 2.6.1. 

  

	 	(b)	Merck shall, by way of the Project Leaders, keep FHT periodically and reasonably informed of Merck meetings with the FDA involving discussions of Collaboration Program Inventions
and Results in connection with milestone events set out in Sections 5.5, 5.6, 5.8 and 5.9. [ * ] . 

  

	 	(c)	Merck shall have sole discretion as to the regulatory strategy and decision making for any Therapeutic Product, Product or Test; provided however, that during the
Collaboration Program Term, Merck shall consider in good faith any and all JCC recommendations regarding regulatory strategy with respect to the use of Collaboration Program Inventions and Results. 

  

	 	(d)	All Marketing Authorizations shall be held by and in the name of Merck (or its Affiliates), and Merck (or its Affiliates) shall own all regulatory submissions in connection
therewith. 

  

	 	2.4.8	Clinical Trial Methodology. The Parties shall collaborate on efforts to: 

  

	 	(i)	study and collect Biological Samples and Data, and optimize Biological Samples and Data handling and processing; and 

  

	 	(ii)	[ * ] 

  

 14 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	2.4.9	Collaboration Program Clinical Studies. FHT is responsible for conducting Collaboration Program Clinical Studies. All CPCSs must be performed under the direction and control
of the JCC, in accordance with the terms of the Work Plan and the applicable JCC-approved study protocol. Each CPCS involving a Merck NCE shall be performed under a separate Clinical Study Agreement based on the form of agreement attached as
Schedule 2.4.9 to this Agreement and executed by the appropriate parties. FHT shall conduct each CPCS in compliance with all FDA regulations relating to Good Clinical Practice and Clinical Trials, and other applicable regulations.

  

	 	(a)	CPCS Protocols. Merck shall be responsible for writing all protocols for CPCSs involving Merck NCEs and other Merck-Controlled compounds. FHT shall be responsible for writing
all other CPCS protocols, and for obtaining all necessary approvals and appropriate informed consents, in writing, for the collection of Biological Samples and Data for each CPCS. All protocols shall be submitted to the JCC for its review and
approval, once they have been reviewed and approved by Merck’s internal scientific review committees. 

  

	 	(b)	Responsibility for CPCS Resources and Costs. Once the JCC has approved a CPCS protocol, FHT shall make available scientific and managerial personnel with sufficient expertise
and experience necessary to coordinate and conduct the CPCS. FHT shall have the right to use a CRO to conduct a Collaboration Program Clinical Study, provided that: (i) Merck consents in advance; (ii) the CRO agrees to use only
facilities approved in advance by Merck; (iii) the CRO is retained by FHT pursuant to a written agreement; and (iv) the terms of such agreement are approved by Merck (not to be unreasonably withheld). During a given year of the
Collaboration Program, to the extent the JCC approves the use by FHT of the services of a CRO in the conduct of any CPCS, and the corresponding budget for such use, and such utilization results in FHT incurring costs during that year over and above
the amounts paid to FHT pursuant to Section 5.3 (with respect to the Initial Term), or Section 5.4.1(b) (with respect to any one-year extension of the Collaboration Program Term), then [ * ] such cost overage that is consistent with the
approved budget, upon completion of such CPCS. 

  

	 	(c)	Requisite Samples. FHT shall use commercially diligent efforts to collect, pursuant to one or more CPCS, and deliver to Merck the following number of Biological Samples and
Data meeting JCC-specified quality control criteria (the “CPCS Samples and Data”): 

  

	 	(i)	In the Initial Term – [ * ] Biological Samples and Data; 

  

	 	(ii)	In the 2nd Collaboration Program Term year
– [ * ] Biological Samples and Data, and 

  

 15 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	(iii)	In the 3rd Collaboration Program Term year
– [ * ] Biological Samples and Data. 

  
 For
the purposes of this subparagraph 2.4.9(c), the term “Requisite Samples” means the number of CPCS-derived Biological Samples and Data required to be collected and delivered to Merck in any given Collaboration Program year as specified
above. For clarity, each “Requisite Sample” would include [ * ] from a [ * ] . A Requisite Sample could thus be [ * ] from a [ * ] , as long as these [ * ] on the [ * ] . 
  
 More than one Requisite Sample may come from [ * ] . Subject to Merck’s funding obligations as set out in
Section 5.3 and 5.4.1, Merck shall not be charged or be liable for any costs, fees or expenses incurred by FHT in connection with FHT’s annual CPCS efforts to obtain and deliver the Requisite Samples. The JCC is authorized to reallocate
the number of Requisite Samples to be collected in any year of the Collaboration Program Term, so that a portion of the Requisite Sample deliverable may be allocated to another Collaboration Program Term year. Any such reallocation shall not impact
Merck’s payment obligations under Sections 5.3 or 5.4.1, and must be expressly agreed upon in writing by FHT (such consent not to be unreasonably withheld). 
  
 FHT shall complete each CPCS that is approved by the JCC to start in a given Collaboration Program Term year by the end of
that year, or as soon as practicable after such year. 
  

	 	(d)	Additional CPCSs. The JCC may authorize CPCSs for the purpose of collecting additional CPCS-derived Biological Samples and Data over and above the Requisite Samples in a
given year of the Collaboration Program Term. In such case, all costs in FHT scientific and managerial personnel time, FHT expenses, and cost of Third Party services for such additional CPCSs shall be estimated in a budget prepared by the Project
Leaders and submitted to the JCC for approval with the understanding that the cost of conducting each such CPCS shall be based upon [ * ] , or the JCC-approved costs charged by any CRO approved pursuant to Section 2.4.4(b) of performing such
CPCS. If the JCC approves the budget for such additional CPCSs, then the Parties will meet and discuss in good faith the appropriate cost allocation between the Parties for the performance of such additional CPCSs. 

  

	 	2.4.10	 Agreements with Third Parties. If during the Collaboration Program Term FHT believes that one or more Third Parties may possess skills, technology or
intellectual property of use to the Parties in the conduct of the Collaboration Program, it shall identify such Third Party to the JCC, and the JCC shall evaluate and recommend to Merck whether or not it should consider entering into discussions
with such Third Party to collaborate with, or license intellectual property from, such Third Party (a “Third Party Collaboration Agreement”). 

  

 16 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
Without limiting the generality of the foregoing, Merck agrees that, in the event that FHT presents to the JCC a Test business opportunity, Merck will
consider (via the JCC) such opportunity in good faith. 

  

	2.5	FHT Representations Regarding Use of Biological Samples and Data. 

  
 With respect to any Biological Samples and Data that have been or are to be collected by FHT and provided by FHT for use in the Collaboration Program, FHT
represents and warrants (i) that it has complied, or shall comply, with all applicable laws, guidelines and regulations relating to the collection and/or use of the Biological Samples and Data and (ii) that it has obtained, or shall
obtain, all necessary approvals and appropriate informed consents, in writing, for the collection and/or use of such Biological Samples and Data in the manner contemplated under this Agreement. FHT shall provide documentation of such approvals and
consents upon Merck’s request. FHT further represents and warrants that such Biological Samples and Data may be used as contemplated in this Agreement without any obligations to the individuals or entities (“Providers”) who
contributed the Biological Samples and Data, including, without limitation, any obligations of compensation to such Providers or any other Third Party for the intellectual property associated with, or commercial use of, the Biological Samples and
Data. 
  

	2.6	Records and Reports. 

  

	 	2.6.1	Records. FHT and Merck shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and
properly reflect all work done and results achieved in the performance of the Collaboration Program by FHT and Merck, respectively, provided, however, Merck is entitled to mask or de-identify all Merck Excluded Merck Compound Rights. FHT will
transfer all CPCS data to Merck’s clinical trial data base, in accordance with procedures to be established by the Parties. In addition, during and after the Collaboration Program Term, Merck shall provide FHT with periodic reports fully and
properly reflecting the use of Collaboration Program Inventions and Results in connection with milestone events set out in Sections 5.5, 5.6, 5.7.2, 5.8 and 5.9. 

  

	 	2.6.2	Copies and Inspection of Records. Merck shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such records of FHT referred to
in Section 2.6.1, and shall maintain such records and the information disclosed therein in confidence in accordance with Section 4.1. Each Party shall have the right to arrange for its employees and/or consultants involved in the
activities contemplated hereunder to visit the offices and laboratories of the other Party during normal business hours and upon reasonable notice, and to discuss the Collaboration Program work and its results in detail with the appropriate
technical personnel. 

  

	2.7	Rights to Collaboration Program Inventions and Results. The entire right, title and interest in: 

  

	 	2.7.1	FHT Independent Inventions and Improvements shall be owned solely by FHT; 

	 	

  

 17 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	2.7.2	Merck Independent Inventions and Improvements and Excluded Merck Compound Rights shall be owned solely by Merck; 

  

	 	2.7.3	FHT Collaboration Program Inventions and Results shall be owned solely by FHT, and are subject to Merck’s license rights under Article 3; 

  

	 	2.7.4	Merck Collaboration Program Inventions and Results shall be owned solely by Merck, and are subject to FHT’s non-exclusive license rights under Article 3, if any; and

  

	 	2.7.5	Joint Collaboration Program Inventions and Results shall be owned jointly by FHT and Merck, and are subject to the applicable license rights under Article 3.

  
 Inventorship will be determined in accordance
with the United States laws of inventorship. 
  

	2.8	Collaboration Program Term. Subject to early termination as provided in Article 8, the term of the Collaboration Program will start on the Effective Date and end on the first
anniversary of the Effective Date (the “Initial Term”), provided, however, Merck is entitled, in its sole discretion, to extend the Initial Term for two additional 12-month periods by notifying FHT of its decision to extend at least
thirty (30) days before the end of the then current term, and paying FHT the extension fees described in Section 5.4.1(a). The Initial Term and subsequent renewal terms (if exercised by Merck) are collectively referred to as the
“Collaboration Program Term.” 

  

	2.9	Exclusive Efforts. During the Collaboration Program Term, FHT and its Down-Stream Affiliates (as defined below) shall work exclusively (even as to FHT and such Down-Stream
Affiliates themselves) with Merck in efforts to collect or study extracted human tissue (whether plaque or blood) to [ * ] for a disease or condition or for [ * ] or [ * ] , including to [ * ] . 

  

	 	2.9.1	Following the Trigger by Merck of both the Product Exclusivity License and the Test Exclusivity License, for a period of [ * ] from the expiration of the Option Period, FHT (and its
Down-Stream Affiliates) shall not work with any Third Party or itself engage in efforts to [ * ] (or any [ * ] associated with the [ * ] such [ * ] was [ * ] ) to identify [ * ] for [ * ] “) or for [ * ] with respect to any [ * ] , including to
conduct [ * ] . 

  

	 	2.9.2	If Merck Triggers the Product Exclusivity License, but not the Test Exclusivity License, for a period of [ * ] from the expiration of the Option Period, FHT (and its Down-Stream
Affiliates) shall not work with any Third Party or itself engage in efforts to [ * ] (or any [ * ] associated with the [ * ] such [ * ] was [ * ] ) to identify [ * ] for [ * ] therapeutic products for any [ * ] , including to conduct [ * ] .

  

 18 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	2.9.3	If Merck Triggers the Test Exclusivity License, but not the Product Exclusivity License, for a period of [ * ] from the expiration of the Option Period, FHT (and its Down-Stream
Affiliates) shall not work with any Third Party or itself engage in efforts to [ * ] (or any [ * ] associated with the [ * ] such [ * ] was [ * ] ) to identify [ * ] for [ * ] with respect to any [ * ] , including to conduct [ * ] .

  

	 	2.9.4	As used in this Section 2.9, “Down-Stream Affiliate” means (a) any corporation or business entity of which fifty percent (50%) or more of the
securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by FHT; or (b) any corporation or business entity of which fifty percent
(50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by FHT or a corporation or business entity described
in (a). 

  

	2.10	No Encumbrances. During the Collaboration Program Term, or at any time after Merck Triggers either the Test Exclusivity License or the Product Exclusivity License, FHT shall
not encumber or convey any rights to Collaboration Program Inventions and Results or Patent Rights. 

  
 ARTICLE 3 LICENSES; EXCHANGE OF INFORMATION; DEVELOPMENT AND COMMERCIALIZATION. 
  

	3.1	FHT License Grants to Merck. 

  

	 	3.1.1	License to Conduct the Collaboration Program. FHT hereby grants Merck a non-exclusive license under (i) FHT Collaboration Program Inventions and Results, (ii) FHT
Collaboration Program Patents, and (iii) FHT Independent Inventions and Improvements, for the sole purposes of enabling Merck to conduct the Collaboration Program activities assigned to Merck or its Affiliates under the Work Plan. The foregoing
license may be sublicensed to Merck Affiliates and to Third Parties acting on behalf of Merck. 

  

	 	3.1.2	Exclusive Access to and Use of Biological Samples and Data. In consideration of the fees set out in Sections 5.2 and 5.4.1, FHT hereby grants Merck and its Affiliates, during
the Collaboration Program Term, an exclusive right to access, test, profile, analyze and use all Biological Samples and Data within the TALON Registry as Merck deems scientifically appropriate. Following the Collaboration Program Term, Merck’s
exclusive access rights to such Biological Samples and Data shall continue when and if it Triggers the Product Exclusivity License or the Test Exclusivity License. If Merck does not Trigger either a Product Exclusivity License or Test Exclusivity
License, Merck’s exclusive access rights to such Biological Samples and Data convert into non-exclusive access rights. 

  

	 	3.1.3	License Grants In and Outside of the Test Field. 

  

	 	(a)	 Non-exclusive License Grants. Upon the Effective Date and subject to the 

  

 19 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
provisions of Section 3.1.3(c), FHT hereby grants to Merck a non-exclusive, sublicensable license in the Territory under FHT Collaboration Program
Patents, and to use FHT Collaboration Program Inventions and Results: 

  

	 	(i)	In the Test Field, subject to the non-exclusivity milestones and royalties described in Sections 5.6 and 5.11; and 

  

	 	(ii)	For all uses outside of the Test Field, subject to the non-exclusivity milestones and royalties described in Sections 5.5 and 5.11. 

  

	 	(b)	Exclusive License Grants 

  

	 	(i)	Effective as provided in Section 3.1.3(c)(i), FHT hereby grants to Merck an exclusive, sublicensable license in the Territory under the Patent Rights, and to use the FHT
Collaboration Program Inventions and Results, in each case solely in the Test Field, subject to the exclusivity milestones and royalties described in Sections 5.9 and 5.11 (“Test Exclusivity License”). 

  

	 	(ii)	Effective as provided in Section 3.1.3(c)(ii), FHT hereby grants to Merck an exclusive, sublicensable license in the Territory under the Patent Rights, and to use the FHT
Collaboration Program Inventions and Results, in each case solely for purposes outside the Test Field, subject to the exclusivity milestones and royalties described in Sections 5.7, 5.8 and 5.11 (“Product Exclusivity License”).

  

	 	(c)	Effectiveness of License Grants. The exclusive license grants of Section 3.1.3(b) shall become effective and the non-exclusive license grants of Section 3.1.3(a)
shall expire as follows: 

  

	 	(i)	The exclusive license grant in Section 3.1.3(b)(i) shall become effective and the non-exclusive license grant of Section 3.1.3(a)(i) shall expire, immediately upon
Merck’s written notice to FHT of its desire to trigger the Test Exclusivity License, subject to Merck’s payment of the fee described in Section 5.9, provided that Merck sends such notice to FHT prior to the expiration of the
Option Period; 

  

	 	(ii)	The exclusive license grant in Section 3.1.3(b)(ii) shall become effective and the non-exclusive license grant of Section 3.1.3(a)(ii) shall expire, immediately upon
Merck’s written notice to FHT of its desire to trigger the Product Exclusivity License, subject to Merck’s payment of the fee described in Section 5.7.1, provided that Merck sends such notice to FHT prior to the expiration of
the Option Period. 

  

 20 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	3.1.4	Non-Exclusive License Grants. If the making, having made, use, offer for sale, sale or import by Merck, its Affiliates and sublicensees of Therapeutic Products or Tests would
infringe during the term of this Agreement a claim of issued letters patent either in existence as of the Effective Date, or claiming priority to an application in existence as of the Effective Date and Controlled by FHT and which patents are not
otherwise covered by the license grant in this Article 3, FHT hereby grants to Merck, to the extent FHT is legally able to do so, a non-exclusive, royalty-free license in the Territory under such issued letters patent for Merck, to develop, make,
have made, use, sell, offer for sale or import Therapeutic Products, Products and Tests in the Territory. Such non-exclusive license is sublicensable, but only to the extent the sublicensee is acting on behalf of Merck or a Merck Affiliate.

  

	3.2	Merck License Grants to FHT. 

  

	 	3.2.1	License to Conduct the Collaboration Program. Merck hereby grants FHT a non-exclusive license under (i) Merck Collaboration Program Inventions and Results,
(ii) Merck Collaboration Program Patents, and (iii) Merck Independent Inventions, and Improvements for the sole purpose of enabling FHT to conduct the Collaboration Program activities assigned to FHT under the Work Plan. The foregoing
license may be sublicensed with the consent of Merck to Third Parties (including CROs) acting on behalf of FHT. 

  

	 	3.2.2	License Grants In and Outside the Test Field; Joint Inventions. 

  

	 	(a)	Test Field. If Merck does not Trigger the Test Exclusivity License in accordance with Section 3.1.3(c)(i), then, effective as of the first day after the
expiration of the Option Period, Merck hereby grants to FHT a non-exclusive, royalty-free, sublicensable license in the Territory under Merck Collaboration Program Patents, and to use Merck Collaboration Program Inventions and Results, in the Test
Field. 

  

	 	(b)	Outside the Test Field. If Merck does not Trigger the Product Exclusivity License in accordance with Section 3.1.3(c)(ii), then, effective as of the first day
after the expiration of the Option Period, Merck grants to FHT a non-exclusive, royalty-free, sublicensable license in the Territory under Merck Collaboration Program Patents, and to use Merck Collaboration Program Inventions and Results, for all
purposes outside the Test Field. 

  

	 	(c)	If Merck does not Trigger the Test Exclusivity License in accordance with Section 3.1.3(c)(i), each Party shall continue to hold its respective one-half interest in and to any
Joint Collaboration Program Inventions and Joint Patent Rights, including the right to sublicense thereunder, for purposes of developing, using and commercializing (i) prognostic test(s) [ * ] and/or (ii) diagnostic test(s) [ * ] ; and/or
(y) [ * ] . 

  

	 	(d)	 If Merck does not Trigger the Product Exclusivity License in accordance 

  

 21 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
with Section 3.1.3(c)(ii), each Party shall continue to hold its respective one-half interest in and to any Joint Collaboration Program Inventions and
Joint Patent Rights, including the right to sublicense thereunder, for purposes of developing, using and commercializing pharmaceutical or biological therapeutics. 

  

	3.3	No Implied Licenses. Except as specifically set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or
otherwise, in any Information disclosed to it under this Agreement or under any patents or patent applications owned or licensed by the other Party or its Affiliates. 

  
 ARTICLE 4 CONFIDENTIALITY AND PUBLICATION. 
  

	4.1	Nondisclosure Obligation. All Information disclosed by one Party to the other Party under this Agreement shall be maintained in confidence by the receiving Party and shall
not be disclosed to any Third Party or used for any purpose except as set forth in this Agreement without the prior written consent of the disclosing Party, except to the extent that such Information: 

  

	 	4.1.1	is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records;

  

	 	4.1.2	is in the public domain by use and/or publication before its receipt from the disclosing Party, or thereafter enters the public domain through no fault of the receiving Party;

  

	 	4.1.3	is subsequently disclosed to the receiving Party, with no restrictions on further disclosure, by a Third Party who may lawfully do so and is not under an obligation of
confidentiality to the disclosing Party; 

  

	 	4.1.4	is developed by the receiving Party independently of Information received from the disclosing Party, as documented by the receiving Party’s business records;

  

	 	4.1.5	is disclosed to governmental or other regulatory agencies in order to obtain patents or to gain or maintain approval to conduct clinical trials or to market Therapeutic Products or
Tests, but such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations; 

  

	 	4.1.6	is disclosed to Affiliates, agents, consultants, and/or other Third Parties on a need-to-know basis for purposes reasonably necessary or advisable for the research and development,
manufacturing and/or marketing of Therapeutic Product and Test (or for such entities to determine their interest in performing such activities) in accordance with this Agreement on the condition that such Third Parties agree to be bound by
confidentiality and non-use obligations that are no less stringent than those confidentiality and non-use provisions contained in this Agreement; provided, however, that the term of confidentiality for such Third Parties shall be no less than
ten (10) years; or 

  

 22 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	4.1.7	is deemed necessary by counsel to the receiving Party to be disclosed to such Party’s attorneys, independent accountants or financial advisors for the sole purpose of enabling
such attorneys, independent accountants or financial advisors to provide advice to the receiving Party, on the condition that such attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations that
are no less stringent than those confidentiality and non-use provisions contained in this Agreement. 

  
 Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or
available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party.

  
 If a Party is required by law, regulation, or judicial or
administrative process to disclose Information that is subject to the non-disclosure provisions of this Section 4.1, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an
opportunity to challenge or limit the disclosure obligations. Information that is disclosed by law, regulation, judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 4.1
and the Party disclosing such Information shall take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Information. 
  

	4.2	 Publication. Merck and FHT each acknowledge the other Party’s interest in publishing the results of its research in order to obtain recognition within
the scientific community and to advance the state of scientific knowledge. Authorship of any publication shall be determined based on the accepted standards used in peer-reviewed, academic journals at the time of the proposed publication. Each Party
also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information. Consequently, except for disclosures permitted pursuant to Section 4.1, either Party, its employees or
consultants wishing to make a publication or presentation disclosing Collaboration Program Inventions and Results during the Collaboration Program Term shall deliver to the other Party a copy of the proposed written publication or an outline of a
presentation at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall have the right (a) to propose modifications to the publication or presentation for patent reasons, or to remove trade
secrets or confidential business information or (b) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay submission or
presentation for a period of ninety (90) days to enable patent applications protecting each Party’s rights in such information to be filed in accordance with Article 7. Upon expiration of such ninety (90) days, the publishing Party
shall be free to proceed with the publication or presentation. If the reviewing Party requests modifications to the publication or presentation, the publishing Party shall edit such publication to prevent disclosure of the applicable trade secret or

  

 23 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
confidential business information prior to submission of the publication or presentation. Any publication or presentation made pursuant to this
Section 4.2 shall acknowledge the contributions made by the reviewing Party. For clarity, FHT is not entitled to publish or disclose Excluded Merck Compound Rights without Merck’s prior written consent. 

  

	4.3	Publicity/Use of Names. No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and no Party shall use the name, trademark, trade name or
logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except
as may be required by law or regulation to which the Party concerned is subject, provided, that in any event the disclosing Party shall use good faith efforts to give the non-disclosing Party an opportunity, with reasonable advance notice, to review
and comment on any proposed disclosure, where practicable. Notwithstanding the foregoing, each Party shall be entitled to announce the execution of this Agreement using the press release attached as Schedule B. Neither disclosures of
information for which consent has previously been obtained, nor information of a similar nature to that which has been previously disclosed publicly with respect to this Agreement, will require advance approval. 

  
 ARTICLE 5 COLLABORATION PROGRAM FUNDING, MILESTONES AND ROYALTIES 
  

	5.1	Initial Collaboration Program Fees. In consideration for the rights and licenses granted to Merck in this Agreement during the Initial Term, and FHT’s performance of its
obligations under this Agreement during the Initial Term, Merck shall make an initial one-time payment of [ * ] no later than fifteen (15) days after the Effective Date. 

  

	5.2	Registry Access and Prospective Registry Fees. 

  

	 	5.2.1	TALON Registry Access. In consideration for Merck’s exclusive rights to the TALON Registry under the Initial Term, Merck shall make a one-time upfront payment of [ * ]
no later than [ * ] days after the Effective Date. If Merck exercises its right to extend the Collaboration Program Term beyond the Initial Term, Merck shall retain full access rights to the Talon Registry. 

  

	 	5.2.2	Prospective Registry Fee. Merck shall make a one-time payment of [ * ] , no later than [ * ] after the JCC notifies Merck that the number and type of Biological Samples and
Data in the Prospective Registry and described in Section 2.4.4 have been collected by FHT and delivered to Merck in accordance with that Section. 

  

	5.3	Initial Clinical Study Funding Fee. As consideration to FHT for conducting CPCSs during the Initial Term pursuant to Section 2.4.9, Merck shall make a one-time upfront
payment of [ * ] no later than [ * ] after the Effective Date. 

  

 24 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	5.4	Additional Payments. In addition to the fees set out in Section 5.1, 5.2 and 5.3, Merck shall pay to FHT the following contingent payments with respect to each of the
following milestones, if the milestone relating to the specified contingent payment is satisfied: 

  

	 	5.4.1	Collaboration Program Term Extension Fees and Funding. 

  

	 	(a)	Merck shall make a one-time payment of [ * ] for each or any 12-month extension of the Collaboration Program Term in accordance with Section 2.8. Each or any such payment is
due no later than [ * ] after the date on which the Collaboration Program Term would have expired if not for the extension. 

  

	 	(b)	Merck shall make a one-time payment of [ * ] for each or any one-year extension of the Collaboration Program Term in accordance with Section 2.8 in consideration of FHT’s
performance of its obligations under Section 2.4.9(c) in the year covered by such extension. Each or any such payment is due no later than [ * ] after the date on which the Collaboration Program Term would have expired if not for the extension

  

	 	5.4.2	Payments if Merck does not Trigger Product Exclusivity License. If Merck does not Trigger the Product Exclusivity License during the Option Period, it shall pay FHT no later
than [ * ] days after the expiration of the Option Period: 

  

	 	(a)	[ * ] , if Merck extended the Collaboration Program Term to twenty four (24) months pursuant to Section 2.8; or 

  

	 	(b)	[ * ] if Merck extended the Collaboration Program Term to thirty six (36) months pursuant to Section 2.8. 

  

	5.5	Therapeutic Product Development Milestones Under the Non-Exclusive License. Provided that Merck has not Triggered the Product Exclusivity License, Merck shall pay to FHT the
following payments no later than thirty (30) days following completion of the following Product development milestones: 

  

	 	(a)	Product Non-Exclusivity Milestone 1. Merck will make a milestone payment to FHT on Initiation of the first Phase III Clinical Trial for each Therapeutic Product, regardless
of Indication, if Merck included [ * ] in the [ * ] it submitted to the FDA for such Phase III Clinical Trial. The milestone payable is: 

  

	 	(i)	[ * ] if the [ * ] included in the [ * ] are [ * ] in support of [ * ] for that Therapeutic Product’s entry into Phase III Clinical Trials; or  

 

	 	(ii)	[ * ] if the [ * ] included in the [ * ] do not provide support for Phase III Clinical Trial [ * ] . 

  

	 	(b)	Therapeutic Product Non-Exclusivity Milestone 2. Merck will pay a milestone of [ * ] on Filing of the first NDA for each Therapeutic Product with a Major Indication in the
first Major Market, if [ * ] are included in that NDA. 

  

 25 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	(c)	Therapeutic Product Non-Exclusivity Milestone 3. Merck will pay a milestone of [ * ] on the first Marketing Authorization for each Therapeutic Product with a Major Indication
in the first Major Market, if [ * ] are included in that Therapeutic Product’s NDA. 

  

	5.6	Test Development Milestones Under the Non-Exclusive License. Provided that Merck has not Triggered the Test Exclusivity License, Merck shall pay to FHT the following amounts
no later than thirty (30) days following completion of the following Test development milestones: 

  

	 	(a)	Test Non-Exclusivity Milestone 1. Merck will pay a milestone of [ * ] to FHT on first Filing for a Test in the first Major Market. 

  

	 	(b)	Test Non-Exclusivity Milestone 2. Merck will pay a milestone of [ * ] to FHT on first Marketing Authorization in the first Major Market. 

  

	5.7	Payments if Merck Triggers the Product Exclusivity License. In order for Merck to make effective the Product Exclusivity License, Merck shall pay to FHT the following
amounts: 

  

	 	5.7.1	Product Exclusivity License Payment. Merck will pay a one-time payment of [ * ] within [ * ] of the date that Merck sends written notice to FHT of its desire to exercise the
Product Exclusivity License pursuant to Section 3.1.3(c)(ii). 

  

	 	5.7.2	Development Candidate Milestones. If, as a result of the profiling activities set forth in Section 2.4.6, (a) Merck obtains [ * ] on a [ * ] and includes those [ *
] in the [ * ] submitted by Merck in support of [ * ] for that [ * ] ; and (b) such [ * ] enters a [ * ] for a [ * ] before the [ * ] of the Effective Date, then Merck will pay FHT [ * ] no later than [ * ] after such Merck NCE achieves
(a) and (b) of this Section 5.7.2. This milestone payment is payable [ * ] . 

  

	 	5.7.3	Therapeutic Product Milestone Make-Up Payment. If Merck Triggers the Product Exclusivity License and a Product development milestone set forth in Section 5.5(a)(i),
5.5(b) or 5.5(c) has been met [ * ] Merck so Triggered the Product Exclusivity License, Merck shall [ * ] to FHT [ * ] with respect to such Therapeutic Product, [ * ] . 

  

	5.8	Therapeutic Product Development Milestones Under the Exclusive License. Provided that Merck has exercised the Product Exclusivity License, Merck shall pay FHT the following
amounts no later than [ * ] following completion of the following Product development milestones: 

  

	 	(a)	 Therapeutic Product Exclusivity Milestone 1: Merck will make a milestone payment to FHT on Initiation of the first Phase III Clinical Trial

  

 26 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
for each Therapeutic Product, [ * ] , if Merck included [ * ] in the [ * ] it submitted to the FDA for such Phase III Clinical Trial. The milestone payable
is: 

  

	 	(i)	[ * ] if the [ * ] included in the [ * ] are [ * ] in support of [ * ] for that Therapeutic Product’s entry into Phase III Clinical Trials; or  

 

	 	(ii)	[ * ] if the [ * ] included in the [ * ] do not provide support for Phase III Clinical Trial [ * ] . 

  

	 	(b)	Therapeutic Product Exclusivity Milestone 2: Merck will pay a milestone of [ * ] on Filing of the first NDA for each Therapeutic Product with a Major Indication
in the first Major Market, if [ * ] are included in that NDA. 

  

	 	(c)	Therapeutic Product Exclusivity Milestone 3: Merck will pay a milestone of [ * ] on the first Marketing Authorization for each Therapeutic Product with a Major
Indication in the first Major Market, if [ * ] are included in that Therapeutic Product’s NDA. 

  

	5.9	Payments if Merck Triggers the Test Exclusivity License. If Merck sends written notice to FHT pursuant to Section 3.1.3(c)(i) of its desire to exercise the Test
Exclusivity License, Merck shall pay FHT a one-time payment of [ * ] within [ * ] of the date that Merck sends such written notice to FHT the Test Exclusivity License. 

  

	 	5.9.1	Test Exclusivity Milestones. In addition, Merck shall make the following milestone payments to FHT no later than [ * ] following completion of the following Test development
milestones: 

  

	 	(a)	Test Exclusivity Milestone 1: Merck will pay a milestone of [ * ] to FHT on [ * ] in the first Major Market. 

  

	 	(b)	Test Exclusivity Milestone 2: Merck will pay a milestone of [ * ] to FHT on [ * ] in the first Major Market. 

  

	5.10	Therapeutic Product and Test Development Milestones – General. The Therapeutic Product development milestones set out in Sections 5.5 and 5.8 and the Test Development
milestones set out in Sections 5.6 and 5.9 are payable [ * ] , upon the [ * ] of each such milestone by a [ * ] or a [ * ] , provided, that in no event will any milestones be payable after the [ * ] of the Effective Date. Different Therapeutic
Products shall be differentiated based upon whether they contain [ * ] as an [ * ] compared to another Therapeutic Product. Different Tests shall be differentiated based upon whether they contain [ * ] within [ * ] as compared to another Test.

  
 For the purposes of clarity, the Parties
acknowledge and agree, that Merck may develop and commercialize [ * ] in various [ * ] , or as a [ * ] , and that all [ * ] of [ * ] containing the same [ * ] , whether as the [ * ] or in a [ * ] , shall be considered the same [ * ] for determining
any milestone payments due. 
  

 27 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	5.11	Royalties on Test and Product Sales. Subject to the terms and conditions of this Agreement, Merck shall pay FHT the following royalties: 

  

	 	(a)	Royalties of Test Net Sales: [ * ] of total annual worldwide Net Sales of Tests in the Territory. 

  

	 	(b)	Royalties of Product Net Sales: royalties calculated on [ * ] basis in an amount equal to: 

  

	 	(i)	Labeled Products – [ * ] of total annual worldwide Net Sales of Labeled Product in the Territory. 

  

	 	(ii)	Dose Ranging Product – [ * ] of total annual worldwide Net Sales of Dose Ranging Product in the Territory. 

  

	 	(iii)	Enhanced Label Products  

  

	 	(1)	[ * ] of [ * ] of each Enhanced Label Product in the Territory [ * ] ; and 

  

	 	(2)	[ * ] of [ * ] of each Enhanced Label Product in the Territory [ * ] 

  

	5.12	Royalties – General. 

  

	 	5.12.1	Product and Test royalties are payable at the rates set out above regardless of whether Merck has exercised the Product Exclusivity License or Test Exclusivity License.

  

	 	5.12.2	Product royalties shall be based only on the highest tier achieved (Labeled Products, Dose Ranging Products or Enhanced Label Products); royalty tiers are not additive.

  

	 	5.12.3	Royalty Term: 

  

	 	(a)	Test Royalty Term. Royalties on Tests at the rate set out above shall be effective on a Test-by-Test and country by country-basis, as of the date of First Commercial Sale of
a particular Test and end upon the expiration of the later of (i) the last-to-expire issued Valid Test Patent Claim on such Test in such country or (ii) [ * ] from First Commercial Sale of such Test in such country, provided, however that
in no event will any royalties be payable on Net Sales of Tests occurring after [ * ] . 

  

	 	(b)	 Product Royalty Term. Royalties on Products at the rates set out above shall be effective, on a Product-by-Product and country-by-country 

  

 28 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
basis, as of the date of First Commercial Sale of a particular Product and end upon the expiration of the later of (i) the expiration date of the
last-to-expire issued Valid Product Patent Claim on such Product in such country or (ii) [ * ] from First Commercial Sale of such Product in such country; provided, however that in no event will any royalties be payable on Net Sales of any
Product occurring after [ * ] . 

  

	 	5.12.4	Conditions on Payment of Royalties. All royalties are subject to the following conditions: 

  

	 	(a)	that only one (1) royalty shall be due with respect to the same unit of Product or Test; 

  

	 	(b)	that no royalties shall be due upon the sale or other transfer among Merck, its Affiliates or sublicensees of Products or Test, but in such cases the royalty shall be due and
calculated upon Merck’s or its Affiliate’s or its sublicensee’s Net Sales to the first independent Third Party; and 

  

	 	(c)	no royalties shall accrue on the disposition of any Product or Test in reasonable quantities by Merck, its Affiliates or sublicenses as samples (promotion or otherwise), as
donations (for example, to non-profit institutions or government agencies for a non-commercial purpose), or for use in a clinical trial. 

  

	 	5.12.5	Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to any Product in any country in the Territory with a royalty rate lower than the
royalty rate provided by Section 5.11, then the royalty rate to be paid by Merck on Net Sales in that country under Section 5.11 shall be reduced to the rate paid by the compulsory licensee. 

  

	5.13	Reports; Payment of Royalty. During the term of this Agreement following the First Commercial Sale of a Product or Test, Merck shall furnish to FHT a quarterly written report
for the Calendar Quarter showing the Net Sales of all Products or Tests subject to royalty payments sold by Merck and its Related Parties in the Territory during the reporting period and the royalties payable under this Agreement. Reports shall be
due on the [ * ] day following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. Merck shall keep complete and accurate records in sufficient
detail to enable the royalties payable to be determined. 

  

	5.14	Audits.  

  

	 	5.14.1	 Upon the written request of FHT and not more than once in each Calendar Year, Merck shall permit an independent certified public accounting firm of nationally
recognized standing selected by FHT and reasonably acceptable to Merck, at FHT’s expense, to have access during normal business hours to such of the records of Merck as may be reasonably necessary to verify the accuracy of the 

  

 29 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
royalty reports hereunder for any year ending not more than [ * ] months prior to the date of such request. The accounting firm shall disclose to FHT only
whether the royalty reports are correct or incorrect and the amount of any discrepancy. No other information shall be provided to FHT. 

  

	 	5.14.2	If such accounting firm correctly identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy within thirty
(30) days of the date FHT delivers to Merck such accounting firm’s written report so correctly concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by FHT. 

 

	 	5.14.3	Merck shall include in each sublicense granted by it pursuant to this Agreement a provision requiring the sublicensee to make reports to Merck, to keep and maintain records of sales
made pursuant to such sublicense and to grant access to such records by FHT’s independent accountant to the same extent required of Merck under this Agreement. 

  

	 	5.14.4	Upon the expiration of [ * ] months following the end of any year, the calculation of royalties payable with respect to such year shall be binding and conclusive upon FHT, and Merck
and its Affiliates and sublicensees shall be released from any liability or accountability with respect to royalties for such year. 

  

	 	5.14.5	FHT shall treat all financial information subject to review under this Section 5.14 or under any sublicense agreement in accordance with the confidentiality and non-use
provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with Merck and/or its Affiliates and sublicensees obligating it to retain all such information in confidence pursuant to such
confidentiality agreement. 

  

	5.15	Payment Exchange Rate. All payments to be made by Merck to FHT under this Agreement shall be made in United States dollars and may be paid by check made to the order of FHT
or bank wire transfer in immediately available funds to such bank account in the United States as may be designated in writing by FHT from time to time. In the case of sales outside the United States, the rate of exchange to be used in computing the
amount of currency equivalent in United States dollars due FHT shall be made at the rate of exchange utilized by Merck in its worldwide accounting system[ * ] in which such sales are recorded by Merck. 

  

	5.16	Income Tax Withholding. If laws, rules or regulations require withholding of income taxes or other taxes imposed upon payments set forth in this Agreement, Merck shall make
such withholding payments as may be required and shall subtract such withholding payments from the payments set forth in this Article 5. Merck shall submit appropriate proof of payment of the withholding taxes to FHT within a reasonable period of
time. 

  

	5.17	 Sharing Certain Sublicense Revenue. If Merck Triggers the Product Exclusivity License or Test Exclusivity License (or both) and subsequently grants a Third
Party a 

  

 30 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
license or sublicense under any Collaboration Program Patent Rights or to use any Collaboration Program Inventions and Results to enable such Third Party
licensee to discover, identify, develop and sell any therapeutic product or any diagnostic or prognostic test then Merck will owe to FHT a percentage of any payments Merck receives as consideration for such license or sublicense, including without
limitation upfront fees, milestone fees, and product royalties (“Merck Licensing Revenue”) as follows: 

  

	 	(i)	[ * ] of Merck Licensing Revenue received by Merck from the Third Party in consideration for a license or sublicense to discover, identify, develop and sell any therapeutic product.

  

	 	(ii)	[ * ] of Merck Licensing Revenue received by Merck from the Third Party in consideration for a license or sublicense to discover, identify, develop and sell any diagnostic or
prognostic test. 

  
 ARTICLE 6 REPRESENTATIONS AND WARRANTIES

  

	6.1	Representations and Warranties of Each Party. Each Party represents and warrants to the other Party that as of the Effective Date: 

  

	 	6.1.1	it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder; 

  

	 	6.1.2	this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; and

  

	6.2	FHT Representations and Warranties. FHT represents and warrants to Merck that as of the Effective Date: 

  

	 	6.2.1	it has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the TALON Registry and the Biological Samples and Data contained
therein; 

  

	 	6.2.2	to the best of FHT’s knowledge, it is the sole and exclusive owner of the TALON Registry all of which are free and clear of any liens, charges and encumbrances that would have
a material effect on the Collaboration Program, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever with respect to the same;

  

	 	6.2.3	 there are no judgments or settlements against or owed by FHT and no pending (or, to the best of FHT’s knowledge, threatened) claims or litigation relating to

  

 31 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
FHT Independent Inventions and Improvements and the TALON Registry, and to the best of FHT’s knowledge, the presently contemplated use of FHT
Independent Inventions and Improvements under the Collaboration Program does not infringe any intellectual property rights owned or possessed by any Third Party; and 

  

	 	6.2.4	FHT has disclosed to Merck all reasonably relevant information known to FHT regarding the FHT Independent Inventions and Improvements, and the TALON Registry, including without
limitation all patent opinions obtained by FHT related thereto. 

  
 ARTICLE 7 PATENT PROVISIONS. 
  

	7.1	Independent Inventions and Improvements 

  

	 	7.1.1	FHT is solely responsible, at its sole discretion, for filing, prosecution, maintenance, defense and enforcement of the FHT Independent Inventions and Improvements.

  

	 	7.1.2	Merck is solely responsible, at its sole discretion, for filing, prosecution, maintenance, defense and enforcement of the Merck Independent Inventions and Improvements.

  

	7.2	Filing, Prosecution and Maintenance of Collaboration Patents. 

  

	 	7.2.1	FHT Collaboration Program Patents: 

  

	 	(a)	The terms of this Section 7.2.1(a) shall apply to all FHT Collaboration Program Patents during the Option Period and, following Merck’s Trigger of the Product Exclusivity
License or the Test Exclusivity License, shall apply to all FHT Collaboration Program Patents that are the subject of such exclusive license(s). FHT shall be initially responsible, at its expense, for the filing, prosecution and maintenance in the
Territory, upon appropriate consultation with Merck, of the FHT Collaboration Program Patents. FHT shall give Merck an opportunity to review the text of any FHT Collaboration Program Patent before filing, shall consult with Merck with respect
thereto, and shall provide Merck with a copy of any FHT Collaboration Program Patents as filed, together with notice of its filing date and serial number. FHT shall keep Merck advised of the status of the actual and prospective patent filings and
upon Merck’s request, shall provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings. FHT shall promptly give notice to Merck of the grant, lapse, revocation, surrender, invalidation or
abandonment of FHT Collaboration Program Patents. If FHT elects not to file, prosecute or maintain a FHT Collaboration Program Patent, FHT shall notify Merck and Merck shall have the right to file, prosecute or maintain such FHT Collaboration
Program Patent, at Merck’s sole expense. In such event, FHT shall execute such documents and perform such acts at FHT’s expense as may be reasonably necessary to transfer to Merck the right to perform such filing, prosecution or
maintenance. 

  

 32 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	(b)	Following expiration of the Option Period, FHT may file, prosecute, maintain, enforce and defend, at its sole discretion, any FHT Collaboration Program Patents that are neither the
subject of an effective Product Exclusivity License nor Test Exclusivity License. 

  

	 	7.2.2	Merck Collaboration Program Patents: Merck is solely responsible, at its sole discretion, for filing, prosecution, maintenance, defense and enforcement of Merck Collaboration
Program Patents. 

  

	7.3	Joint Collaboration Program Patents. 

  

	 	7.3.1	Merck shall have the first right to file, prosecute and maintain Joint Collaboration Program Patents. Merck may elect not to file, prosecute, or maintain any Joint Collaboration
Program Patents, on a country by country basis, and if so shall notify FHT of that decision. FHT shall reply to such notice within forty-five (45) days, indicating whether it wishes to take over filing, prosecuting and/or maintaining of any
Joint Collaboration Program Patent that is the subject of the notice. In the absence of a reply within that forty-five (45) day period, Merck has no further responsibility for the Joint Collaboration Patent that is the subject of the notice. If
FHT provides a notice assuming responsibility, FHT may subsequently elect not to file, prosecute, or maintain Joint Collaboration Program Patents, on a country by country basis, and if so shall notify Merck of that decision. Merck shall reply to
such notice within forty-five (45) days, indicating whether it wishes to take over filing, prosecuting and/or maintaining Joint Collaboration Program Patent that is the subject of the notice. In the absence of a reply within that forty
(45) day period, FHT has no further responsibility for the Joint Collaboration Patent that is the subject of the notice. 

  

	 	7.3.2	Each Party shall execute such documents and perform such acts as reasonably necessary for the filing, prosecution or maintenance of Joint Collaboration Program Patents. The Party
responsible for the filing, prosecution or maintenance of a particular Joint Collaboration Program Patent (the “Filing Party”) shall give the other Party (the “Non-Filing Party”) an opportunity to review the text of the
application before filing, shall consult with the Non-Filing Party with respect thereto, and shall supply the Non-Filing Party with a copy of the application as filed, together with notice of its filing date and serial number. The Filing Party shall
keep the Non-Filing Party advised of the status of the actual and prospective patent filings and upon request, shall provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings. The Filing Party
shall promptly give notice of any Joint Collaboration Program Patents grant, lapse, revocation, surrender, invalidation or abandonment. 

  

	 	7.3.3	The Filing Party is responsible for all official fees. Each Party is responsible for its own costs and attorney fees 

  

 33 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	7.4	Interference, Opposition, Reexamination and Reissue. 

  

	 	7.4.1	Within ten (10) days of learning of any request for, or filing or declaration of, any interference, opposition, reissue or reexamination relating to FHT Collaboration Program
Patents exclusively licensed or subject to an exclusive license option, FHT shall inform Merck of such event. Merck and FHT shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. Merck shall
have the right to review and approve any submission to be made in connection with such proceeding. 

  

	 	7.4.2	FHT shall not initiate any reexamination, interference or reissue proceeding relating to FHT Collaboration Program Patent Rights exclusively licensed or subject to Merck’s
exclusive license option without the prior written consent of Merck, which consent shall not be unreasonably withheld. 

  

	 	7.4.3	In connection with any interference, opposition, reissue, or reexamination proceeding relating to FHT Collaboration Program Patent Rights exclusively licensed or subject to an
exclusive license option, Merck and FHT will cooperate fully and will provide each other with any information or assistance that either may reasonably request. FHT shall keep Merck informed of developments in any such action or proceeding,
including, to the extent permissible by law, consultation and approval of any settlement, the status of any settlement negotiations and the terms of any offer related thereto. 

  

	 	7.4.4	FHT shall bear the expense of any interference, opposition, reexamination, or reissue proceeding relating to FHT Collaboration Program Patent Rights. 

  

	 	7.4.5	For Joint Collaboration Program Patents exclusively licensed, or subject to the exclusive license option described in this Agreement, the Filing Party is treated in the same manner
as FHT is treated in Sections 7.4.1-7.4.4. 

  

	 	7.4.6	For Joint Collaboration Program Patents where Merck does not Trigger the Product Exclusivity License or Test Exclusivity License, Merck and FHT shall consult and cooperate fully to
determine a course of action with respect to any items addressed in Sections 7.4.1-7.4.4. 

  

	7.5	Enforcement and Defense. 

  

	 	7.5.1	Each Party shall give the other party notice of either (i) any infringement of Joint Collaboration Program Patent Rights and FHT Collaboration Program Patent Rights exclusively
licensed or subject to an exclusive license option, or (ii) any misappropriation or misuse of Joint Collaboration Program Inventions and Results or FHT Collaboration Program Inventions and Results that are exclusively licensed or subject to the
exclusive license option described in this Agreement, that may come to its attention. Merck and FHT shall thereafter consult and cooperate fully to determine a course of action, including but not limited to the commencement of legal action by either
or both Merck and FHT, to terminate such infringement or misappropriation or misuse. Each Party shall have the right to be represented by counsel of its own choice and expense. 

  

 34 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	(a)	FHT, upon notice to Merck, shall have the first right to initiate and prosecute legal action at its own expense and in the name of FHT and/or Merck, or to control the defense of any
declaratory judgment action relating to FHT Collaboration Program Patent Rights or FHT Collaboration Program Inventions and Results that are exclusively licensed or subject to the exclusive license option described in this Agreement. FHT shall
promptly inform Merck if it elects not to exercise such first right and Merck shall thereafter have the right to either initiate and prosecute such action or to control the defense of such declaratory judgment action in the name of Merck and, if
necessary, FHT. 

  

	 	(b)	Merck, upon notice to FHT, shall have the first right to initiate and prosecute legal action at its own expense and in the name of FHT and/or Merck, or to control the defense of any
declaratory judgment action relating to Joint Collaboration Program Patent Rights or Joint Collaboration Program Inventions and Results that are exclusively licensed or subject to the exclusive license option described in this Agreement. Merck shall
promptly inform FHT if it elects not to exercise such first right and FHT shall thereafter have the right to either initiate and prosecute such action or to control the defense of such declaratory judgment action in the name of FHT and, if
necessary, Merck. 

  

	 	(c)	Merck and FHT shall consult and cooperate fully to determine a course of action with respect to Joint Collaboration Program Patent Rights and Joint Collaboration Program Inventions
and Results, where Merck does not Trigger the Product Exclusivity License or Test Exclusivity License. 

  

	 	7.5.2	For any action to terminate any infringement under 7.5.1, if a Party is unable to initiate or prosecute such action solely in its own name, the other Party will join such action
voluntarily and will execute and cause its Affiliates to execute all documents necessary to initiate litigation to prosecute and maintain such action, all at the expense (limited to out-of-pocket costs) of the Party initiating such action. In
connection with any action, Merck and FHT will cooperate fully and will provide each other with any information or assistance that either may reasonably request. Each Party shall keep the other informed of developments in any action or proceeding,
including, to the extent permissible by law, consultation on and approval of any settlement, the status of any settlement negotiations and the terms of any offer related thereto. 

  

	 	7.5.3	Any recovery obtained by [ * ] Merck and FHT in connection with or as a result of any action contemplated by this Section 7.5, whether by settlement or otherwise, shall be
shared in order as follows: 

  

	 	(a)	 [ * ] shall recoup [ * ] of its costs and expenses incurred in connection with the action; 

  

 35 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	(b)	[ * ] shall then, to the extent possible, recover [ * ] costs and expenses incurred in connection with the action; and 

  

	 	(c)	the amount of any recovery remaining shall then be allocated between the Parties [ * ] taking into consideration the [ * ] . 

  

	 	7.5.4	FHT shall inform Merck of any certification regarding any Patent Rights it has received pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its
successor provisions or any similar provisions in a country in the Territory other than the United States, and shall provide Merck with a copy of such certification within five (5) days of receipt. FHT’s and Merck’s rights with
respect to the initiation and prosecution of any legal action as a result of such certification or any recovery obtained as a result of such legal action shall be as defined in Section 7.5.3 provided, however, that FHT shall
exercise its first right to initiate and prosecute any action and shall inform Merck of such decision within ten (10) days of receipt of the certification, after which time Merck shall have the right to initiate and prosecute such action.
Regardless of which Party has the right to initiate and prosecute such action, both Parties shall, as soon as practicable after receiving notice of such certification, convene and consult with each other regarding the appropriate course of conduct
for such action. The non-initiating Party shall have the right to be kept fully informed and provide input regarding the appropriate course of conduct for such action, and the right to join and participate in such action using its own counsel at its
expense. 

  

	7.6	Patent Term Restoration. The Parties hereto shall cooperate with each other, including without limitation to provide necessary information and assistance as the other Party
may reasonably request, in obtaining patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory where applicable to Patent Rights exclusively licensed to Merck. If elections with respect to
obtaining such patent term restoration are to be made, Merck shall have the right to make the election, subject to good faith consultation with FHT, and FHT agrees to abide by such election. 

  
 ARTICLE 8 TERM AND TERMINATION 
  

	8.1	Term and Expiration. This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Sections 8.2 or 8.3, this Agreement shall continue
in effect until expiration of all royalty obligations hereunder. Upon expiration of this Agreement, (a) Merck’s licenses under Article 3 shall become fully paid-up, perpetual licenses; and (b) FHT’s license granted pursuant to
Section 3.2.2, if in effect at such time, will become a perpetual, fully-paid up license. 

  

	8.2	 Termination by Merck of the Collaboration Program. Notwithstanding anything contained in this Agreement to the contrary, Merck shall have the right to
terminate the Collaboration Program at any time in its sole discretion by giving ninety (90) days’ advance written notice to FHT. In the event of the termination by Merck of the 

  

 36 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
Collaboration Program under this Section 8.2, the “Option Period” shall then be deemed to extend only until thirty (30) days following
the effective date of such termination. If Merck terminates the Collaboration Program and does not Trigger either the Test Exclusivity License or the Product Exclusivity License, the non-exclusive license grants set forth in Sections 3.1.3 and 3.2.2
shall remain in effect. In addition, provided that Merck has not Triggered the Product Exclusivity License prior to terminating the Collaboration Program, Merck shall pay to FHT the appropriate payment specified in Section 5.4.2 (a) or
(b) no later than 15 days after the expiration of the Option Period. 

  
 Termination by Merck of the Collaboration Program under this Section 8.2 shall not affect Merck’s continued obligation to pay milestones and royalties as set forth in Article 5. No later than thirty
(30) days after the effective date of such termination, each Party shall return or cause to be returned to the other Party all Information in tangible form received from the other Party and all copies thereof; provided, however, that
each Party may retain any Information reasonably necessary for such Party’s continued practice under the non-exclusive licenses referred to above, and may keep one copy of Information received from the other Party in its confidential files for
record purposes. 
  

	8.3	Termination for Cause. 

  

	 	8.3.1	Cause for Termination. This Agreement may be terminated at any time during the term of this Agreement: 

  

	 	(a)	upon written notice by either Party if the other Party is in breach of its material obligations hereunder by causes and reasons within its control and has not cured such breach
within ninety (90) days after notice requesting cure of the breach; provided, however, in the event of a good faith dispute with respect to the existence of a material breach, the ninety (90) day cure period shall be tolled until
such time as the dispute is resolved pursuant to Section 9.7; and provided, further, that neither Party shall be entitled to terminate this Agreement or any rights and obligations of the Parties hereunder, due to any such breach by the
other Party of its obligations under Article 4 (Confidentiality or Publication), but in such case: (i) the non-breaching Party remains entitled to pursue, all rights and remedies at law or in equity available to it (including, but not limited
to monetary damages); and (ii) if Merck is the non-breaching Party in such instance, Merck may reduce milestone and/or royalty obligations by the amount of the monetary damages suffered by Merck as a result of the material breach of this
Agreement by FHT to the extent those damages have been determined pursuant to Section 9.7, or 

  

	 	(b)	by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets
for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such
proceeding is not dismissed within ninety (90) days after the filing thereof. 

  

 37 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	8.3.2	Effect of Termination for Cause on License. 

  

	 	(a)	If Merck terminates this Agreement under Section 8.3.1(a) or (b), then in addition to any other remedies available to Merck at law or in equity: 

  

	 	(i)	Merck retains the exclusive right to access the TALON Registry (and the Biological Samples and Data contained therein), for any purpose, including to support regulatory filings, and
to the extent [ * ] the TALON Registry or any portion of the Prospective Registry or the CPCS Samples and Data, FHT shall [ * ] such [ * ] to Merck in accordance with Merck’s instructions; 

  

	 	(ii)	Merck’s licenses pursuant to Sections 3.1 and 3.1.4 shall become perpetual licenses, subject to continued payment of milestones and royalties thereon as provided in Article 5;
provided that, Merck may reduce milestone and/or royalty obligations by the amount of the monetary damages suffered by Merck as a result of the material breach of this Agreement by FHT to the extent those damages have been determined pursuant
to Section 9.7, and provided, further, that if such grounds for termination is a material breach of FHT’s [ * ] , Merck’s licenses pursuant to Sections 3.1 and 3.1.4 shall become perpetual exclusive licenses, without payment of
any fees as provided in Section 5.7.1 or 5.9, and Merck shall only be obligated to pay FHT milestones and royalties following the effective date of such termination at a rate which is [ * ] of the rate that would otherwise be payable pursuant
to Article 5 if this Agreement had not been so terminated with respect to either Products and/or Tests; 

  

	 	(iii)	Merck’s obligations under the Collaboration Program and under Section 2.4.6 shall terminate; 

  

	 	(iv)	FHT’s licenses pursuant to Section 3.2 from Merck shall terminate, and Merck will have no obligations under Section 5.4.2; 

  

	 	(v)	FHT shall, within thirty (30) days after the effective date of such termination shall return or cause to be returned to Merck all Information in tangible form, as well as any
Excluded Merck Compound Rights; and 

  

	 	(vi)	except as specified in this Section 8.3.2(a) and the surviving obligations specified in Section 8.4, all rights and obligations under this Agreement shall terminate as of
such termination date. 

  
  

 38 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	(b)	If FHT terminates this Agreement under Section 8.3.1(a) or (b), then in addition to any other remedies available to FHT at law or in equity: 

  

	 	(i)	Merck’s licenses pursuant to Sections 3.1 and 3.1.4 shall terminate as of such termination date, and Merck’s exclusive access to the TALON Registry (and any Biological
Samples and Data contained therein) shall terminate; 

  

	 	(ii)	FHT’s licenses pursuant to Sections 3.2.2 shall survive and become perpetual licenses; 

  

	 	(iii)	FHT’s obligations under the Collaboration Program shall terminate; 

  

	 	(iv)	Merck shall, within thirty (30) days after the effective date of such termination return or cause to be returned to FHT all Information in tangible form; and

  

	 	(v)	except as specified in this Section 8.3(b), and the surviving obligations specified in Section 8.4, all rights and obligations under this Agreement shall terminate as of
such termination date. 

  
 If this Agreement is
terminated by Merck pursuant to Section 8.3.1(b) due to the rejection of this Agreement by or on behalf of FHT under Section 365 of the United States Bankruptcy Code (the “Code”), all licenses and rights to licenses
granted under or pursuant to this Agreement by FHT to Merck are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of
the Code. The Parties agree that Merck, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against FHT
under the Code, Merck shall be entitled to [ * ] , any such [ * ] and all embodiments of such [ * ] . Such [ * ] shall be promptly delivered to Merck (i) upon any such commencement of a bankruptcy proceeding upon written request therefore by
Merck, unless FHT elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of FHT upon written request therefore by Merck. The
foregoing provisions of Section 8.3.2 are without prejudice to any rights Merck may have arising under the Code or other applicable law. 
  

	8.4	 Effect of Expiration or Termination; Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to
such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without
limitation the obligation to pay royalties for Product(s) or Test(s) sold prior to such expiration or termination. The provisions of Article 4 shall survive the expiration or termination of this Agreement and shall continue in effect for ten
(10) years. In addition, the provisions of Article 1, Article 6, Article 7 (to the extent provided therein) and Sections 2.5. 2.7, 2.9 (to the extent 

  

 39 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
provided for therein), 2.10. 3.1.2 (to the extent provided therein), 3.1.3 (unless otherwise provided for in Section 8.3.2(b)), 3.1.4, 3.2.2 (to the
extent Merck does not Trigger the Test Exclusivity License or the Product Exclusivity License, and unless otherwise provided for in Section 8.3.2(a)), 5.12, 8.3.2. 9.1, 9.4-9.16 shall survive any expiration or termination of this Agreement.

  
 ARTICLE 9 MISCELLANEOUS 
  

	9.1	Indemnification. 

  

	 	9.1.1	Except to the extent due to the negligence or willful misconduct of Merck, FHT shall indemnify, defend and hold Merck and its Affiliates, and their respective directors, officers,
employees and agents, harmless from and against any claims of damages, bodily injury, death, or property damage made by a Third Party (a “Third Party Claim”) to the extent arising from: (i) the negligence or willful misconduct of FHT
under this Agreement; (ii) any liability due to FHT Independent Inventions and Improvements or patent infringement due to FHT’s Collaboration Program activities; (iii) the material breach by FHT of any warranty, representation or
obligation of FHT under this Agreement; or (iv) the development, testing, use, marketing, sale, storage or handling by FHT or its representatives or agents under this Agreement of any FHT Independent Inventions and Improvements.

  

	 	9.1.2	Except to the extent due to the negligence or willful misconduct of FHT, Merck shall indemnify, defend and hold FHT and its Affiliates, and their respective directors, officers,
employees and agents, harmless from and against any Third Party Claim resulting from: (i) the negligence or willful misconduct of Merck, or patent infringement due to Merck’s Collaboration Program activities, under this Agreement;
(ii) any liability due to Merck Independent Inventions and Improvements or patent infringement due to Merck’s Collaboration Program activities; (iii) the material breach by Merck of any warranty, representation or obligation of Merck
under this Agreement; or (iii) the development, testing, synthesis, use, storage, handling, manufacture or commercialization by Merck or its representatives or agents under this Agreement of any Therapeutic Product, Product, Test, Merck NCE, or
any Merck Independent Inventions and Improvements. 

  

	 	9.1.3	 If a Party (the “Indemnitee”) intends to claim indemnification under this Section, it shall promptly notify the other Party (the “Indemnitor”)
in writing of any Third Party Claim for which the Indemnitee intends to claim such indemnification. The failure of the Indemnitee to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action shall
relieve the Indemnitor of any obligation to the Indemnitee under this Section with respect to any such action. The Indemnitee shall permit the Indemnitor to control the litigation and/or settlement of such Third Party Claim, and cooperate fully with
Indemnitor in all matters related thereto, provided that unless agreed by Indemnitee (i) counsel appointed by Indemnitor to defend Indemnitee shall not 

  

 40 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
take any position which if sustained would cause Indemnitee not to be indemnified by Indemnitor and (ii) no settlement will involve any terms binding on
Indemnitee except payment of money to by paid by Indemnitor. 

  

	 	9.1.4	Neither Party shall be liable to the other for indirect, consequential, special or punitive damages under this Agreement. 

  

	9.2	Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any
obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including, but not limited to, embargoes, war, acts of war (whether war be
declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party.
The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. 

  

	9.3	Assignment and Change of Control. 

  

	 	9.3.1	Except as provided in this Section 9.3, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by
either Party without the consent of the other Party. 

  

	 	9.3.2	Merck may, without consent of FHT, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of Merck or in its entirety to the successor
party connection with a Change of Control. 

  

	 	9.3.3	FHT may, without the consent of Merck, assign this Agreement and its rights and obligations hereunder in whole or in part to any Affiliate of FHT or in its entirety to the successor
party in connection with a Change of Control. 

  

	 	9.3.4	If there is a FHT Change of Control that is [ * ] , then FHT shall provide written notice to Merck no later than [ * ] following the public announcement of such Change of Control,
and Merck shall have the right, at Merck’s election at any time after the consummation of such Change of Control to implement some or all of the following revisions to this Agreement: 

  

	 	(a)	Merck may limit its obligations to provide FHT royalty reports pursuant to Section 5.13 [ * ] obligations, and not its sales on a [ * ] ; provided that, Merck will, if
requested by FHT, provide [ * ] specified in such Section 5.13 to an independent certified public accounting firm for auditing in accordance with Section 5.14. 

  

	 	(b)	 Merck may terminate [ * ] of its [ * ] under the Collaboration Program, and/or exercise its unilateral right to terminate the Collaboration Program 

  

 41 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
as provided in Section 8.2, provided that the amounts owed FHT under Section 5.4.2 shall not be owed in such case. In the event Merck elects
to so terminate early the Collaboration Program pursuant to Section 8.2, and where the effective date of such termination by Merck is within [ * ] following the public announcement date of such [ * ] transaction, Merck shall be required only to
pay FHT [ * ] of the amounts set out in Sections 5.7.1 and 5.9 if it Triggers the Product Exclusivity License or the Test Exclusivity License. 

  

	 	(c)	In the event Merck does not Trigger the Product Exclusivity License, Merck will have no obligations under Section 5.4.2. 

  

	 	(d)	Following Merck’s Triggering of the Product Exclusivity License or Test Exclusivity License, Merck shall have the right to require FHT and/or the surviving entity, to adopt
reasonable procedures to be agreed upon in writing with Merck to prevent the disclosure of all Information of Merck and other information with respect to the development and commercialization of Tests and Products (collectively “Sensitive
Information”) beyond FHT personnel having access to and knowledge of Sensitive Information prior to the Change of Control and to control the dissemination of Sensitive Information disclosed after the Change of Control. The purposes of such
procedures shall be to strictly limit such disclosures to only those personnel having a need to know Sensitive Information in order for FHT to perform its obligations under this Agreement and to prohibit the use of Sensitive Information for
competitive reasons against Merck and its Related Parties and Compounds or Tests, including without limitation, the use of Sensitive Information for the development or commercialization of competing products or tests. 

  
 Any attempted assignment not in accordance with this Section 9.3 shall
be void. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. 
  

	9.4	Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained in this Agreement shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties
shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

  

	9.5	Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by
personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

  

 42 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

			
	if to FHT, to:	  	 FoxHollow Technologies, Inc.
 740 Bay Road

Redwood City, California 94063
 Attention: Vice President, Corporate
Development
 Facsimile No.: [ * ]

		
	with a copy to:	  	 Cooley Godward LLP
 Five Palo Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306-2155
 Attention: Barbara A. Kosacz, Esq.
 Facsimile No.: (650)
849-7400

		
	if to Merck, to:	  	 Merck & Co., Inc.
 One Merck Drive
 P.O. Box 100, WS3A-65
 Whitehouse Station, NJ 08889-0100
 Attention: Office of Secretary
 Facsimile No.: [ * ]

		
	And	  	 Merck & Co., Inc.
 One Merck Drive
 Attention: Chief Licensing Officer
 P.O. Box 100, WS2A-30
 Whitehouse Station, NJ 08889-0100
 Facsimile: [ * ]

  
 or to such other
address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile
on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day
following the date of mailing, if sent by mail. 
  

	9.6	Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to its conflict of laws principals,
and the patent laws of the United States. 

  

	9.7	Dispute Resolution. 

  

	 	9.7.1	 The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the
breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an “Excluded Claim” 

  

 43 
 [ *
] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 

	 	 
shall be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes
of the American Arbitration Association (“AAA”), and judgment on the arbitration award may be entered in any court having jurisdiction thereof. 

  

	 	9.7.2	The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business: within thirty (30) days after initiation of arbitration, each Party
shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the
third arbitrator, the third arbitrator shall be appointed by the AAA. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. 

  

	 	9.7.3	Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may,
without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no
authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any
administrative fees of arbitration. 

  

	 	9.7.4	Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration
without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New
York statute of limitations. 

  

	 	9.7.5	The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution
of the dispute through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such
payments are not due. 

  

	 	9.7.6	As used in this Section, the term “Excluded Claim” shall mean a dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or
copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

  

	9.8	 Entire Agreement; Amendments. This Agreement, together with its Schedules and Exhibits, contains the entire understanding of the Parties with respect to the
subject matter of this Agreement and supercedes and cancels all previous express or implied agreements and understandings, negotiations, writings and commitments, either oral or 

  

 44 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

	 	 
written, in respect to that subject matter. The Schedules and Exhibits to this Agreement are incorporated in this Agreement by reference and shall be deemed
a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties. 

  

	9.9	Headings. The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and
reading the several Articles and Sections hereof. 

  

	9.10	Independent Contractors. It is expressly agreed that FHT and Merck shall be independent contractors and that the relationship between the two Parties shall not constitute a
partnership, joint venture or agency. Neither FHT nor Merck shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written
consent of the other Party. 

  

	9.11	Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a
waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. 

  

	9.12	Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this
Agreement or otherwise available under law. 

  

	9.13	Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.
Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

  

	9.14	Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to an
Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other
gender, (b) words such as “in this Agreement”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular
shall include the plural, and vice versa. 

  

	9.15	Business Day Requirements. If a notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a business day then such
notice or other action or omission shall be deemed to require to be taken on the next occurring business day. 

  

	9.16	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

  

 45 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective
Date. 
  

							
	MERCK & CO., INC.	    	 	 	FOXHOLLOW TECHNOLOGIES, INC.
				
	BY:	 	 /s/ Judy C. Lewent

	    	BY:	 	 /s/ Robert W. Thomas

	 	 	Judy C. Lewent	    	 	 	Robert W. Thomas
				
	TITLE:	 	 Executive Vice President
 and Chief Financial
Officer
	    	TITLE:	 	President and Chief Executive Officer
	 	 	 	    	 	 	 

  

 46 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 SCHEDULES AND EXHIBITS 
  
 Work Plan 
  
 Press Release 
  

  
 Exhibit 1.61 TALON Registry Description 

 
 TALON Registry contains approximately [ * ] samples, collected
from [ * ] patients. 
  
 Schedule 2.4.9

  
 Clinical Study Agreement form of agreement 
  

 47 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 EXHIBIT 1.61 
  
 [ * ] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 2.1 
 Research Plan 
  
 [ * ]

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

			
	

	 	

  
 Merck &
Inc. Signs Novel Research and Drug Development 
 Agreement with FoxHollow Technologies 
  
 Deal Marks the First Pharmaceutical-Medical Device Partnership Aimed at

 Identifying Cardiovascular Biomarkers for Use as Diagnostics and as Tools 
 for Drug Development 
  
 WHITEHOUSE STATION, NJ and REDWOOD CITY, CA – Sept. 14, 2005 – Merck & Co., Inc. and FoxHollow Technologies announced today the formation of a novel pharmacogenomics collaboration. The collaboration will focus on
analyzing atherosclerotic plaque removed from patient arteries as a means of identifying new biomarkers of atherosclerotic disease progression for use in the development of cardiovascular compounds in Merck’s pipeline. 
  
 The agreement includes a research collaboration of up to three years. As part
of the collaboration, FoxHollow will provide exclusive access to atherosclerotic plaque samples collected from patients who have cardiovascular disease and have been treated with the SilverHawkTM Plaque Excision System. The SilverHawk System is
a minimally invasive catheter system used to remove atherosclerotic plaque, which blocks blood flow in the arteries. The device is used to treat peripheral arterial disease, a condition that affects 12 million Americans and can lead to severe,
debilitating leg pain, and possibly, amputation. 
  
 Merck’s
responsibilities include analyzing the collected plaque samples to identify biomarkers and profiling compounds using these biomarker platforms. 
  
 “We currently assess risk of heart disease using blood markers such as cholesterol, blood pressure, blood sugar and CRP, but none of these provides a
direct view of the immediate cause of disease which is atherosclerotic plaque.” said Richard Pasternak, M.D., Vice President Clinical Research at Merck. “Our collaboration with FoxHollow has the potential to provide insight on
cardiovascular disease and to accelerate development of novel drugs for this widespread health issue.” 
  
 Under the terms of the agreement, Merck will make initial cash payments of $9 million to FoxHollow to cover the first year of the collaboration. If Merck
elects to continue the collaboration, then it will pay FoxHollow additional payments of up to $31 million in the following two years. FoxHollow will also receive milestone payments and royalties based upon achieving program objectives. 

 

 — more — 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 “It is our greatest hope and expectation that this partnership will lead to a more precise
understanding of cardiovascular disease, and result in innovative new medicines that are specific for an individual patient” said John Simpson, Ph.D., M.D., Chairman of the Board of FoxHollow Technologies. “As an undisputed leader in
advancing cardiovascular medicine, Merck is the best possible partner for this collaboration. We are thrilled to be a part of such a groundbreaking exploration of a disease area that remains little understood and significantly undertreated.”

  
 About Merck 
  
 Merck & Co., Inc. is a global research-driven pharmaceutical
company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories. The Company devotes extensive efforts to increase access to
medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit
www.merck.com. 
  
 Merck’s Forward Looking Statement

  
 This press release contains “forward-looking
statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The
forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties
that affect Merck’s business, particularly those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K, which the company
incorporates by reference. 
  
  

 — more — 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 About FoxHollow Technologies, Inc, 
  
 FoxHollow Technologies, Inc. (NASDAQ: FOXH) cannot provide any assurance that the clinical results announced above will be
replicated at other hospitals in the future. FoxHollow develops and markets minimally invasive plaque excision devices for the treatment of peripheral artery disease (PAD). An estimated 12 million people in the U.S. are thought to suffer from
PAD with 2.5 million patients currently diagnosed. PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The
SilverHawk System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet. For more information, please visit our website at www.foxhollowtech.com. 
  

			
	Press Contacts:	 	 
		
	Merck & Co., Inc.	 	FoxHollow Technologies, Inc.
		
	Amy Rose	 	Leslie Trigg
	(908) 423-6537	 	(650) 421-8539
		
	Investor Contact:	 	 
		
	Merck & Co., Inc.	 	 
		
	Graeme Bell	 	 
	(908) 423-5185	 	 

  
 # # # 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 ON THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 This Schedule 2.4.9 is an integral part of the Collaboration and License Agreement between Merck and
Co., Inc. and FoxHollow Technologies, Inc. (the “Collaboration Agreement”) to which it is attached. The rights and obligations set out in this schedule shall be in addition to the rights and obligations set out in the Collaboration
Agreement, and may be modified or supplemented in accordance with Section 9.8 of the Collaboration Agreement. All capitalized terms used but not defined in this Schedule have the meanings ascribed to them in the Collaboration Agreement.

  
 [ * ] 
  

 — more — 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 ON THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED.Restated 1996 Flexible Stock Incentive Plan

 Exhibit 10.2 
  
 INFOSPACE, INC. 
 RESTATED 1996 FLEXIBLE STOCK INCENTIVE PLAN 
  

	1.	Establishment, Purpose, and Definitions. 

  

	 	(a)	There is hereby adopted the Restated 1996 Flexible Stock Incentive Plan (the “Plan”) of InfoSpace, Inc., a Delaware corporation (the “Company”).

  

	 	(b)	The purpose of the Plan is to provide a means whereby eligible individuals (as defined in paragraph 4, below) can acquire Common Stock of the Company (the
“Stock”). The Plan provides employees (including officers and directors who are employees) of the Company and of its Affiliates an opportunity to purchase shares of Stock pursuant to options which may qualify as incentive stock
options (referred to as “incentive stock options”) under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), and employees, officers, directors, independent contractors, and consultants
of the Company and of its Affiliates an opportunity to purchase shares of Stock pursuant to options which are not described in Section 422 or 423 of the Code (referred to as “nonqualified stock options”). The Plan also
provides for the sale or bonus of Stock to eligible individuals in connection with the performance of services for the Company or its Affiliates. Finally, the Plan authorizes the grant of stock appreciation rights (“SARs”), either
separately or in tandem with stock options, entitling holders to cash compensation measured by appreciation in the value of the Stock. 

  

	 	(c)	The term “Affiliates” as used in the Plan means parent or subsidiary corporations, as defined in Sections 424(e) and (f) of the Code (but substituting
“the Company” for “employer corporation”), including parents or subsidiaries which become such after adoption of the Plan. 

  

	2.	Administration of the Plan. 

  

	 	(a)	 The Plan shall be administered by the Board of Directors of the Company (the “Board”) or a committee or committees (which term includes
subcommittees) appointed by, and consisting of one or more members of, the Board (the “Plan Administrator”). If and so long as the Common Stock is registered under Section 12(b) or 12(g) of the Exchange Act, the Board shall
consider in selecting the Plan Administrator and the membership of any committee acting as Plan Administrator, with respect to any persons subject or likely to become subject to Section 16 of the Exchange Act, the provisions regarding
(i) ”outside directors” as contemplated by Section 162(m) of the Code and (ii) ”nonemployee 

	 	 
directors” as contemplated by Rule 16b-3 under the Exchange Act. The Board may delegate the responsibility for administering the Plan with respect to
designated classes of eligible Participants to different committees consisting of one or more members of the Board, subject to such limitations as the Board or the Plan Administrator deems appropriate. Committee members shall serve for such term as
the Board may determine, subject to removal by the Board at any time. 

  

	 	(b)	The Plan Administrator shall determine which eligible individuals (as defined in paragraph 4, below) shall be granted options under the Plan, the timing of such grants, the
terms thereof (including any restrictions on the Stock), and the number of shares subject to such options. 

  

	 	(c)	The Plan Administrator may amend the terms of any outstanding option granted under this Plan, but any amendment which would adversely affect the Optionee’s rights under an
outstanding option shall not be made without the Optionee’s written consent. The Plan Administrator may, with the Optionee’s written consent, cancel any outstanding stock option or accept any outstanding stock option in exchange for a new
option. Notwithstanding the foregoing, any change or adjustment to an incentive stock option shall not, without the Optionee’s written consent, be made in a manner so as to constitute a “modification” that would cause such incentive
stock option to fail to continue to qualify as an incentive stock option. 

  

	 	(d)	The Plan Administrator shall also determine which eligible individuals (as defined in paragraph 4, below) shall be issued Stock or SARs under the Plan, the timing of such
grants, the terms thereof (including any restrictions), and the number of shares or SARs to be granted. The Stock shall be issued for such consideration (if any) as the Plan Administrator deems appropriate. Stock issued subject to restrictions shall
be evidenced by a written agreement (the “Restricted Stock Purchase Agreement” or the “Restricted Stock Bonus Agreement”). The Plan Administrator may amend any Restricted Stock Purchase Agreement or Restricted Stock
Bonus Agreement, but any amendment which would adversely affect the stockholder’s rights to the Stock shall not be made without his or her written consent. 

  

	 	(e)	The Plan Administrator shall have the sole authority, in its absolute discretion to adopt, amend, and rescind such rules and regulations as, in its opinion, may be advisable for the
administration of the Plan, to construe and interpret the Plan, the rules and the regulations, and the instruments evidencing options or Stock granted under the Plan and to make all other determinations deemed necessary or advisable for the
administration of the Plan. All decisions, determinations, and interpretations of the Plan Administrator shall be binding on all participants. 

  

 - 2 - 

	3.	Stock Subject to the Plan. 

  

	 	(a)	An aggregate of not more than 45,967,866 shares of Stock shall be available for the grant of stock options or the issuance of Stock under the Plan plus an annual increase to be
added on the first day of the Company’s fiscal year beginning in 2002 equal to the lesser of (i) five percent (5%) of the Company’s outstanding shares of Stock on the last day of the preceding fiscal year, and (ii) a lesser
amount determined by the Board of Directors. If an option is surrendered (except surrender for shares of Stock) or for any other reason ceases to be exercisable in whole or in part, the shares which were subject to such option but as to which the
option had not been exercised shall continue to be available under the Plan. Any Stock which is retained by the Company upon exercise of an option in order to satisfy the exercise price for such option or any withholding taxes due with respect to
such option exercise shall be treated as issued to the Optionee and will thereafter not be available under the Plan. 

  

	 	(b)	If there is any change in the Stock subject to the Plan, an Option Agreement, a Restricted Stock Purchase Agreement, a Restricted Stock Bonus Agreement, or a SAR Agreement through
merger, consolidation, reorganization, recapitalization, reincorporation, stock split, stock dividend, or other change in the capital structure of the Company, appropriate adjustments shall be made by the Plan Administrator in order to preserve but
not to increase the benefits to the individual, including adjustments to the aggregate number, kind and price per share of shares subject to the Plan, an Option Agreement, a Restricted Stock Purchase Agreement, a Restricted Stock Bonus Agreement, or
a SAR Agreement. 

  

	4.	Eligible Individuals. Individuals who shall be eligible to have granted to them the options, Stock or SARs provided for by the Plan shall be such employees, officers,
directors, independent contractors and consultants of the Company or an Affiliate as the Plan Administrator, in its discretion, shall designate from time to time. Notwithstanding the foregoing, only employees of the Company or an Affiliate
(including officers and directors who are bona fide employees) shall be eligible to receive incentive stock options. 

  

	5.	The Option Price. 

  

	 	(a)	 The exercise price of the Stock covered by each incentive stock option shall be not less than the per share fair market value of such Stock on the date the option
is granted. The exercise price of the Stock covered by each nonqualified stock option shall be as determined by the Plan Administrator. In the case of a nonqualified stock option intended to qualify as “performance-based compensation”
within the meaning of Section 162(m) of the Code, the per share exercise price of the Stock shall be no less than 100% of the fair market value per share of the Stock on the 

  

 - 3 - 

	 	 
date of grant. Notwithstanding the foregoing, in the case of an incentive stock option granted to a person possessing more than ten percent of the combined
voting power of the Company or an Affiliate, the exercise price shall be not less than 110 percent of the fair market value of the Stock on the date the option is granted. The exercise price of an option shall be subject to adjustment to the
extent provided in paragraph 3(b), above. 

  

	 	(b)	The fair market value shall be as established in good faith by the Plan Administrator or (i) if the Stock is listed on the Nasdaq National Market, the fair market value shall
be the closing selling price for the stock as reported by the Nasdaq National Market for a single day or (ii) if the Stock is listed on the New York Stock Exchange or the American Stock Exchange, the fair market value shall be the closing
selling price for the Stock as such price is officially quoted in the composite tape of transactions on such exchange for a single trading day. If there is no such reported price for the Stock for the date in question, then such price on the last
preceding date for which such price exists shall be determinative of the fair market value. 

  

	6.	Terms and Conditions of Options. 

  

	 	(a)	Each option granted pursuant to the Plan will be evidenced by a written Stock Option Agreement executed by the Company and the person to whom such option is granted.

  

	 	(b)	The Plan Administrator shall determine the term of each option granted under the Plan; provided, however, that the term of an incentive stock option shall not be for more than
7 years and that, in the case of an incentive stock option granted to a person possessing more than ten percent of the combined voting power of the Company or an Affiliate, the term shall be for no more than five years.

  

	 	(c)	In the case of incentive stock options, the aggregate fair market value (determined as of the time such option is granted) of the Stock with respect to which incentive stock options
are exercisable for the first time by an eligible employee in any calendar year (under this Plan and any other plans of the Company or its Affiliates) shall not exceed $100,000. In the event the Optionee holds two or more such options that become
exercisable for the first time in the same calendar year, such limitation shall be applied on the basis of the order in which such options are granted. 

  

	 	(d)	 The Stock Option Agreement may contain such other terms, provisions and conditions not inconsistent with this Plan as may be determined by the Plan Administrator.
If an option, or any part thereof is intended to qualify 

  

 - 4 - 

	 	 
as an incentive stock option, the Stock Option Agreement shall contain those terms and conditions which are necessary to so qualify it.

  

	 	(e)	The following limitations shall apply to grants of stock options: 

  

	 	(i)	No individual shall be granted, in any fiscal year of the Company, stock options to purchase more than 8,000,000 shares of Stock. 

  

	 	(ii)	In connection with his or her initial service, an individual may be granted stock options to purchase up to an additional 8,000,000 shares of Stock which shall not count against the
limit set forth in subsection (i) above. 

  

	 	(iii)	The foregoing limitations shall be adjusted proportionately in connection with any change in the Company’s capitalization. 

  

	 	(iv)	If a stock option is cancelled in the same fiscal year of the Company in which it was granted (other than in connection with a transaction described in Section 15), the
cancelled stock option will be counted against the limits set forth in subsections (i) and (ii) above. For this purpose, if the exercise price of a stock option is reduced, the transaction will be treated as a cancellation of the stock
option and the grant of a new stock option. 

  

	7.	Terms and Conditions of Stock Purchases and Bonuses. 

  

	 	(a)	Each sale or grant of stock pursuant to the Plan will be evidenced by a written Restricted Stock Purchase Agreement or Restricted Stock Bonus Agreement executed by the Company and
the person to whom such stock is sold or granted. 

  

	 	(b)	The Restricted Stock Purchase Agreement or Restricted Stock Bonus Agreement may contain such other terms, provisions and conditions consistent with this Plan as may be determined by
the Plan Administrator, including not by way of limitation, restrictions on transfer, forfeiture provisions, repurchase provisions and vesting provisions. To the extent required by applicable law, any right of the Company to repurchase stock granted
pursuant to a restricted stock purchase or restricted stock bonus at the original purchase price, if the right is assignable, the assignee must pay the Company upon assignment of the right cash equal to the difference between the original price and
fair value if the original purchase price is less than fair value. 

  

	 	(c)	 The purchase price of Stock sold hereunder pursuant to a Restricted Stock Purchase Agreement shall be the price determined by the Plan Administrator on the date the
right to purchase Stock is granted; provided, however that (i) such price shall not be less than 85% of the per share fair 

  

 - 5 - 

	 	 
market value of such Stock on the date the right to purchase Stock is granted and (ii) to the extent required by applicable law, in the case of any
person who owns Company stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, such price shall be 100% of the per share fair market value of such Stock at the time the right to purchase Stock is
granted, or at the time the purchase is consummated. 

  

	8.	Terms and Conditions of SARs. The Plan Administrator may, under such terms and conditions as it deems appropriate, authorize the issuance of SARs evidenced by a written SAR
agreement (which, in the case of tandem options, may be part of the option agreement to which the SAR relates) executed by the Company and the person to whom such SAR is granted. The SAR agreement may contain such terms, provisions and conditions
consistent with this Plan as may be determined by the Plan Administrator. 

  

	9.	Use of Proceeds. Cash proceeds realized from the sale of Stock under the Plan shall constitute general funds of the Company. 

  

	10.	Amendment, Suspension, or Termination of the Plan. 

  

	 	(a)	The Board may at any time amend, suspend or terminate the Plan as it deems advisable; provided that such amendment, suspension or termination complies with all applicable
requirements of state and federal law, including any applicable requirement that the Plan or an amendment to the Plan be approved by the Company’s stockholders, and provided further that, except as provided in paragraph 3(b), above, the
Board shall in no event amend the Plan in the following respects without the consent of stockholders then sufficient to approve the Plan in the first instance: 

  

	 	(i)	To increase the maximum number of shares subject to incentive stock options issued under the Plan; or 

  

	 	(ii)	To change the designation or class of persons eligible to receive incentive stock options under the Plan. 

  

	 	(b)	No option may be granted nor any Stock issued under the Plan during any suspension or after the termination of the Plan, and no amendment, suspension or termination of the Plan
shall, without the affected individual’s consent, alter or impair any rights or obligations under any option previously granted under the Plan. The Plan shall terminate with respect to the grant of incentive stock options on April 10,
2006, unless previously terminated by the Board pursuant to this paragraph 10. 

  

	11.	 The Plan Administrator shall establish and set forth in each instrument that evidences an option whether the option will continue to be exercisable, and the

  

 - 6 - 

	 	 
terms and conditions of such exercise, if an Optionee ceases to be employed by, or to provide services to, the Company or an Affiliate, which provisions may
be waived or modified by the Plan Administrator at any time. 

  

	12.	Assignability. Each option granted pursuant to this Plan shall, during Optionee’s lifetime, be exercisable only by him, and the option shall not be transferable by
Optionee by operation of law or otherwise other than by will or the laws of descent and distribution. Notwithstanding the foregoing, and to the extent permitted by Section 422 of the Code, the Plan Administrator, in its sole discretion, may
permit such transfer, assignment and exercisability and may permit an Optionee to designate a beneficiary who may exercise the option after the Optionee’s death; provided, however, that any option so transferred or assigned shall be subject to
all the same terms and conditions contained in the instrument evidencing the option. Stock subject to a Restricted Stock Purchase Agreement or a Restricted Stock Bonus Agreement shall be transferable only as provided in such Agreement.

  

	13.	Payment Upon Exercise of Options. 

  

	 	(a)	 Payment of the purchase price upon exercise of any option granted under this Plan shall be made in cash, a certified check, bank draft, postal or express money
order payable to the order of the Company, provided, however, that the Plan Administrator, in its sole discretion, may permit an Optionee to pay the option price in whole or in part (i) tendering (either actually or, if and so long as the Stock
is registered under Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), shares of Stock owned by the Optionee for at least six months (or any shorter period necessary to avoid a charge to
the Company’s earnings for financial reporting purposes) on the day prior to the exercise date equal to the aggregate option exercise price; (ii) if and so long as the stock is registered under Section 12(b) or 12(g) of the Exchange
Act, by delivery on a form prescribed by the Plan Administrator of an irrevocable direction to a securities broker approved by the Plan Administrator to sell shares and deliver all or a portion of the proceeds to the Company in payment for the
Stock; (ii) by delivery of the Optionee’s promissory note with such full recourse, interest, security, and redemption provisions as the Plan Administrator in its discretion determines appropriate; or (iii) in any combination of the
foregoing. The amount of any promissory note delivered in connection with an incentive stock option shall bear interest at a rate specified by the Plan Administrator but in no case less than the rate required to avoid imputation of interest (taking
into account any exceptions to the imputed interest rules) for federal income tax purposes. In addition, the Plan Administrator, in its sole discretion, may authorize the surrender by an Optionee of all or part of an unexercised option and authorize
a payment in consideration thereof of an amount equal to the difference between the aggregate fair market value of the Stock subject to 

  

 - 7 - 

	 	 
such option and the aggregate option price of such Stock. In the Plan Administrator’s discretion, such payment may be made in cash, shares of Stock with
a fair market value on the date of surrender equal to the payment amount, or some combination thereof. The purchase price for shares purchased under an option may also be paid by such other consideration as the Plan Administrator may permit.

  

	 	(b)	In the event that the exercise price is satisfied by the Plan Administrator retaining from the shares of Stock otherwise to be issued to Optionee shares of Stock having a value
equal to the exercise price, the Plan Administrator may issue Optionee an additional option, with terms identical to this option agreement, entitling Optionee to purchase additional Stock in an amount equal to the number of shares so retained.

  

	14.	Withholding Taxes. 

  

	 	(a)	No Stock shall be granted or sold under the Plan to any participant, and no SAR may be exercised, until the participant has made arrangements acceptable to the Plan Administrator
for the satisfaction of federal, state, and local income and social security tax withholding obligations, including without limitation obligations incident to the receipt of Stock under the Plan, the lapsing of restrictions applicable to such Stock,
the failure to satisfy the conditions for treatment as incentive stock options under applicable tax law, or the receipt of cash payments. Upon exercise of a stock option or lapsing or restriction on stock issued under the Plan, the Company may
satisfy its withholding obligations by withholding from the Optionee or requiring the stockholder to surrender shares of the Company’s Stock sufficient to satisfy federal, state, and local income and social security tax withholding obligations.

  

	 	(b)	In the event that such withholding is satisfied by the Company or the Optionee’s employer retaining from the shares of Stock otherwise to be issued to Optionee shares of Stock
having a value equal to such withholding tax, the Plan Administrator may issue Optionee an additional option, with terms identical to the option agreement under which the option was received, entitling Optionee to purchase additional Stock in an
amount equal to the number of shares so retained. 

  

	15.	Corporate Transaction. 

  

	 	(a)	For purposes of this Section 15, a “Corporate Transaction” shall include any of the following stockholder-approved transactions to which the Company is a
party: 

  

	 	(i)	 a merger or consolidation in which the Company is not the surviving entity, except for (1) a transaction the principal purpose 

  

 - 8 - 

	 	 
of which is to change the state of the Company’s incorporation, or (2) a transaction in which the Company’s stockholders immediately prior to
such merger or consolidation hold (by virtue of securities received in exchange for their shares in the Company) securities of the surviving entity representing more than fifty percent (50%) of the total voting power of such entity immediately
after such transaction; 

  

	 	(ii)	the sale, transfer or other disposition of all or substantially all of the assets of the Company unless the Company’s stockholders immediately prior to such sale, transfer or
other disposition hold (by virtue of securities received in exchange for their shares in the Company) securities of the purchaser or other transferee representing more than fifty percent (50%) of the total voting power of such entity
immediately after such transaction; or 

  

	 	(iii)	any reverse merger in which the Company is the surviving entity but in which the Company’s stockholders immediately prior to such merger do not hold (by virtue of their shares
in the Company held immediately prior to such transaction) securities of the Company representing more than fifty percent (50%) of the total voting power of the Company immediately after such transaction. 

  

	 	(b)	 In the event of any Corporate Transaction, any option or outstanding SAR shall terminate and any restricted stock shall be reconveyed to or repurchased by the
Company immediately prior to the specified effective date of the Corporate Transaction; provided, however, that to the extent permitted by applicable law and unless otherwise determined by the Plan Administrator in its discretion (and reflected in
the applicable written agreement evidencing the grant of the award), any unvested option, SAR or any restricted stock shall vest and become exercisable as to 25% of the unvested shares, or become nonforfeitable as to 25% of the forfeitable shares,
as applicable, immediately prior to the specified effective date of the Corporate Transaction. Notwithstanding the foregoing, options, SARs or restricted stock shall not terminate if, in connection with the Corporate Transaction, they are to be
assumed or substituted by the successor corporation or its parent company. Unless otherwise determined by the Plan Administrator in its discretion (and reflected in the applicable written agreement evidencing the grant of the award), if options,
SARs or restricted stock are not assumed or substituted by the successor corporation or its parent pursuant to options, SARs or restricted stock agreements providing substantially equal value and having substantially equivalent provisions as the
options, SARs or restricted stock granted pursuant to this Plan, such options, SARs or restricted stock shall vest and become exercisable or nonforfietable, as applicable, as to an additional 

  

 - 9 - 

	 	 
25% of the unvested shares or forfeitable shares, immediately prior to the specified effective date of the Corporate Transaction.

  

	16.	Stockholder Approval. This Plan shall only become effective with regard to incentive stock options upon its approval by a majority of the stockholders voting (in person or by
proxy) at a stockholders’ meeting held within 12 months of the Board’s adoption of the Plan. The Plan Administrator may grant incentive stock options under the Plan prior to the stockholders’ meeting, but until stockholder
approval of the Plan is obtained, no incentive stock option shall be exercisable. 

  

	17.	Information to Plan Participants. The Company shall provide to each Plan participant, during any period for which said participant has one or more options or SARs or shares
acquired pursuant to the Plan outstanding, copies of annual reports of the Company issued during said period. 

  

	18.	No Trust or Fund. The Plan is intended to constitute an “unfunded” plan. Nothing contained herein shall require the Company to segregate any monies or other
property, or shares of Stock, or to create any trusts, or to make any special deposits for any immediate or deferred amounts payable to any Optionee, and no Optionee shall have any rights that are greater than those of a general unsecured creditor
of the Company. 

  

	19.	Severability. If any provision of the Plan or any option is determined to be invalid, illegal or unenforceable in any jurisdiction, or as to any person, or would disqualify
the Plan or any option under any law deemed applicable by the Plan Administrator, such provision shall be construed or deemed amended to conform to applicable laws, or, if it cannot be so construed or deemed amended without, in the Plan
Administrator’s determination, materially altering the intent of the Plan or the option, such provision shall be stricken as to such jurisdiction, person or option, and the remainder of the Plan and any such option shall remain in full force
and effect. 

  

 - 10 - 

 INFOSPACE, INC. 
 RESTATED 1996 FLEXIBLE STOCK INCENTIVE PLAN 
 AMENDMENTS 
  

					
	 Section

	  	 Effect of Amendment

	  	Effective Date of
Amendment

			
	3(a)	  	Pursuant to 5/24/99 shareholder approved amendment to annually increase number of shares reserved for issuance under the Plan, increased the maximum number of shares available for issuance under
the Plan from 10,000,000 to 11,491,966.	  	January 1, 2000
			
	3(a)	  	Increased maximum number of shares available for issuance under the Plan from 11,491,966 to 22,983,933 to reflect 2-for-1 forward stock split approved by the Board 11/29/99 and effective on
1/4/00.	  	January 4, 2000
			
	3(a)	  	Increased maximum number of shares available for issuance under the Plan from 22,983,933 to 45,967,866 to reflect 2-for-1 forward stock split approved by the Board January 21, 2000 and effective
on 4/6/00.	  	April 6, 2000
			
	15(b)	  	“Housekeeping” amendment to delegate authority and discretion to the Plan Administrator with respect to the applicability of the acceleration provision provided for in Section 15(b) of
the 1996 Plan to grants under that Plan.	  	January 25, 2002
			
	3(a)	  	Amendment to Evergreen Provision to provide for an annual increase in the number of shares reserved for grant of options or issuance of stock to 5%.	  	April 15, 2002
			
	6(b)	  	Amended to change term from 10 years to seven.	  	February 22, 2003

  

 - 11 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]